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In this thesis, gene therapeutic 
approaches for the treatment 
of lymphedema and peripheral 
ischemia, which result from 
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Adenoviral VEGF-C and VEGF-D 
were shown to induce robust 
lymphangiogenesis and, subsequently, 
improve lymphatic flow. Furthermore, 
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by adenovirally delivered hypoxia-
inducible factors was shown to 
enhance the recovery of ischemic 
muscles from energy depletion 
induced by exercise.
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ABSTRACT 
In this thesis, stimulation of the growth of both lymphatic and blood vessels was studied in 
large animal models using adenovirally (Ad) delivered vascular endothelial growth factors 
(VEGFs) and hypoxia-inducible factors (HIFs), which transcriptionally regulate a plethora 
of factors involved in angiogenesis, including VEGF-A isoforms. 
Two recognized lymphangiogenic growth factors, VEGF-C and VEGF-D, were employed 
to induce lymphatic vessel growth in a new large animal model of lymphedema. 
Lymphedema, which often develops as a consequence of the surgical removal of cancer or 
radiation therapy, lacks curative treatments, thus making the application of gene therapy to 
repair lymphatic damage an attractive new treatment option for the patients suffering from 
this condition. Both AdVEGF-C and AdVEGF-D were shown to induce lymphatic vessel re-
growth and, consequently, improve lymphatic flow in the pig model of lymphedema, 
where lymphatic damage was first caused by excising all of the lymphatic vessels around 
an inguinal lymph node. Interestingly, AdVEGF-D was found to evoke more pronounced 
blood vascular effects than AdVEGF-C. Therefore, VEGF-C gene therapy was selected for 
further evaluation and optimization in the same large animal model of lymphedema. A 
subsequent comparison was performed of VEGF-C gene transfer into the lymph node 
versus into the fat surrounding the lymph node in terms of efficacy and adverse effects. The 
regeneration of lymphatic vessels was equally effective regardless of the gene transfer site. 
However, gene transfer into the fat surrounding the lymph node was found to have less 
adverse effects on the node. 
In the final part of this thesis, HIF-1α and HIF-2α, which are upstream regulators of 
VEGF-A expression, were adenovirally delivered to mouse myocardium and ischemic 
rabbit hindlimbs to evaluate their capability to induce blood vessel growth. Patients with 
cardiovascular disease are becoming increasingly older and suffering additional comorbid 
conditions, i.e. they may not withstand the current invasive procedures but would be 
suitable for these emerging alternative treatment options. Both of the transcription factors 
increased blood capillary size and perfusion in skeletal muscles. Additionally, HIF-1α gene 
transfer enhanced the recovery of ischemic muscles from energy depletion induced by 
electrical stimulation. 
In conclusion, adenovirally delivered VEGF family members VEGF-C and VEGF-D 
efficiently induce lymphangiogenesis, which results in improved lymphatic flow, whereas 
AdHIF-1α triggers angiogenesis, which is sufficient to improve energy metabolism of 
ischemic muscles. 
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TIIVISTELMÄ 
 
Tässä väitöskirjassa tutkittiin adenovirusvälitteisesti (Ad) yliekspressoitujen verisuonen 
endoteelin kasvutekijäperheen (vascular endothelial growth factor, VEGF) jäsenten sekä 
hapenpuutteessa aktivoituvien transkriptiotekijöiden (hypoxia-inducible factor, HIF) kykyä 
saada aikaan imu- ja verisuonten uudiskasvua isoeläinmalleissa. HIF-1α ja HIF-2α 
säätelevät useita verisuonten uudismuodostukseen osallistuvia tekijöitä, mukaan lukien 
VEGF-A:ta.   
Väitöskirjan ensimmäisessä osatyössä kehitettiin uusi lymfedeeman isoeläinmalli, jonka 
avulla tutkittiin tunnettujen lymfangiogeneettisten kasvutekijöiden VEGF-C:n ja VEGF-D:n 
kykyä aikaansaada imusuonten uudismuodostusta imunestekierron parantamiseksi. 
Lymfedeema eli imunesteturvotus kehittyy usein syövän kirurgisen poiston tai sädetyksen 
seurauksena, eikä siihen ole olemassa parantavaa hoitoa. Imusuonten uudismuodostus 
geeniterapian avulla voisi tarjota uuden hoitovaihtoehdon lymfedeemasta kärsiville 
potilaille. Lymfedeema aiheutettiin tuhoamalla sian nivusen imusolmuketta ympäröivät 
imutiet, minkä jälkeen imusolmukkeeseen tehtiin AdVEGF-C- tai AdVEGF-D-geeninsiirto. 
Molemmat kasvutekijät saivat aikaan voimakasta imusuonten muodostusta ja paransivat 
imunestekiertoa, mutta VEGF-D:n havaittiin aiheuttavan lisäksi huomattavia 
verisuonivaikutuksia. Tästä johtuen VEGF-C valikoitui toisen osatyön kohteeksi, jossa 
verrattiin imusolmukkeen sisään tehtyä AdVEGF-C-geeninsiirtoa imusolmuketta 
ympäröivään rasvaan tehtyyn geeniinsiirtoon tehokkuuden ja haittavaikutusten osalta. 
Imusuonten uudiskasvu oli yhtä tehokasta geeninsiirtopaikasta riippumatta, mutta rasvaan 
tehdyn geeninsiirron havaittiin olevan suotuisampi imusolmukkeen kannalta.  
Väitöskirjan viimeisessä osatyössä tutkittiin AdHIF-1α:n ja AdHIF-2α:n kykyä saada 
aikaan verisuonten uudiskasvua hiiren sydämessä ja kanin hapenpuutteesta kärsivässä 
takaraajassa. Sydän- ja verisuonitautipotilaat ovat yhä vanhempia ja kärsivät usein 
liitännäissairauksista, mikä rajoittaa nykyisten kajoaviavien hoitotoimenpiteiden käyttöä 
heidän kohdallaan ja luo tarpeen vaihtoehtoisten hoitomuotojen kehittämiselle. Molemmat 
transkriptiotekijät HIF-1α ja HIF-2α saivat aikaan verisuonikapillaarien laajentumista ja 
verenkierron lisääntymistä luurankolihaksessa. Lisäksi AdHIF-1α-geeninsiirron osoitettiin 
parantavan iskeemisen lihaksen energiavarastojen palautumista sähköisesti tuotetun 
lihassupistelun aiheuttamasta energiavajeesta. 
Yhteenvetona voidaan todeta, että adenovirusvälitteinen geeninsiirto VEGF-C:llä tai 
VEGF-D:llä johtaa voimakkaaseen imusuonten uudismuodostukseen sekä parantuneeseen 
imunestekiertoon, kun taas AdHIF-1α aikaansaa verisuonten uudiskasvua, joka on riittävää 
parantamaan hapenpuutteesta kärsivän lihaksen palautumista rasituksesta. 
 
Luokitus: QU 107, QU 560, QZ 170, WG 500, WH 700 
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1 Introduction 
 
Gene therapy comprises a set of strategies which modify the expression of specific genes in an 
attempt to treat or prevent diseases. Although still in its infancy, it holds promise for treating a 
wide range of diseases, including several cardiovascular diseases. Cardiovascular diseases are 
still the leading cause of death globally, despite major progress in current treatment practices 
(WHO 2014). The pathophysiology of these diseases involves a process called atherosclerosis, in 
which lipid accumulation and inflammation lead to a gradual occlusion of arteries and 
consequently to ischemia (Libby 2002). Cardiovascular gene therapy aims at stimulating 
vascular growth in order to ensure sufficient blood flow to the tissue suffering from ischemia 
(Yla-Herttuala, Martin 2000). This can be achieved by therapeutically over-expressing proteins 
that are essential for the formation of new blood vasculature. Vascular endothelial growth 
factors (VEGFs) govern the sprouting of new blood vessels from pre-existing vessels, termed as 
angiogenesis, and they have been widely used for vascular therapeutic purposes (Ribatti, 
Crivellato 2012). A single administration of VEGF-A evokes intense angiogenic effects, but also 
can evoke severe side effects such as tissue edema (Rissanen et al. 2005). Therefore, it has been 
postulated that upstream regulators of VEGF expression, such as hypoxia-inducible factors 
(HIFs), would represent a better therapeutic target than a single angiogenic factor since HIFs are 
able to activate multiple angiogenic growth factors as well as regulating many of the genes 
involved in energy metabolism and recovery of ischemic tissues (Semenza 2012). As a result of 
multiple growth factors working in harmony, the angiogenic response may be more 
physiological than anything that can be achieved by one individual factor. 
Parallel to blood vascular circulatory system in mammals there exists another vascular 
network that transports a plasma-derived, milk-like fluid called lymph from the peripheral 
tissues back to the central blood circulation (Breslin 2014). Insufficiency of this lymphatic 
vascular system may lead to lymphedema, which is a debilitating condition characterized by 
gross swelling of the affected part of the body (Warren et al. 2007). In the industrialized 
countries, lymphedema often develops as a consequence of surgical or radiotherapeutic 
interventions for cancer (Rockson, Rivera 2008). Apart from cardiovascular gene therapy, where 
angiogenic growth factors are administered to achieve therapeutic blood vessel growth in 
ischemic tissues, gene therapy may also be employed to stimulate the growth of new lymphatic 
vessels and thus to ameliorate the symptoms of lymphedema. Two vascular endothelial growth 
factor family members, VEGF-C and VEGF-D, are known to be stimulators of 
lymphangiogenesis; these factors have been demonstrated to restore lymphatic drainage to a 
site of lymphatic damage in experimental rodent models (Tammela et al. 2007, Yoon et al. 2003, 
Szuba et al. 2002). 
The aim of this thesis was to utilize large animal models to clarify the lymphangiogenic 
potential of two adenovirally delivered single growth factors, VEGF-C and VEGF-D, and 
moreover, to study whether the adenoviral application of a “master-switch” agent, such as HIF-
1α/-2α, which is responsible for the coordinated induction of multiple angiogenic factors, 
would lead to a more physiological response than could be achieved with the administration of 
a single growth factor, such as VEGF-A.  
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2 Review of the literature 
2.1 DISEASES OF THE BLOOD AND LYMPHATIC VASCULAR SYSTEM 
2.1.1 Atherosclerosis 
Atherosclerosis is a disease of large arteries and the underlying pathogenic process behind 
ischemia affecting the lower extremities, the heart and the brain. There are several recognized 
risk factors for atherosclerosis including high serum LDL (low-density lipoprotein) and low 
HDL (high-density lipoprotein) levels, hypertension, diabetes, smoking, obesity and lack of 
exercise. The atherosclerotic process involves the accumulation of lipids into the subendothelial 
space, the infiltration of inflammatory cells, intracellular lipid accumulation in macrophages 
and smooth muscle cells (SMCs), the migration and proliferation of medial SMCs within the 
inflamed intima, fibrous cap formation, and finally calcification and neovascularization within 
the plaque. (Libby 2002, Lusis 2000.) Initially, the lesion grows towards the adventitia until, 
after a certain point, it begins to protrude into and obstruct the vessel lumen (Lusis 2000). The 
progressive narrowing of the arterial lumen impairs blood flow and leads to the first clinical 
manifestations: ischemic pain at stress and later also at rest. Rupture of an atherosclerotic lesion 
and the concomitant thrombosis are responsible for major cardiovascular events, such as 
sudden death, myocardial infarction or stroke. (Libby 2002.) Although the root cause of the 
inflammatory process remains as yet undefined, endothelial dysfunction is considered to be the 
preceding step prior to LDL entry within the arterial intima, and thus, it can be considered as 
the basis for the development of angiopathy (Badimon, Vilahur 2012).  
 
2.1.2 Peripheral arterial disease 
Peripheral arterial disease (PAD) refers to the narrowing of arteries distal to the arch of aorta, 
including carotid, vertebral, upper extremity, mesenteric, renal and lower extremity vascular 
sites (Figure 1) (European Stroke Organisation 2011). The total disease prevalence ranges 
between 3 and 15% increasing up to 20% with age (Norgren et al. 2007). The risk factors for 
PAD include the typical risk factors for atherosclerotic disease, such as smoking, hypertension, 
diabetes and dyslipidemia (European Stroke Organisation et al. 2011). The lower extremity 
artery disease (LEAD) has different presentations that can be categorized according to the 
Fontaine (stages I-IV) or the Rutherford classification (grades 0-III). The most typical symptom 
is intermittent claudication: pain in the calves that increases with walking and disappears 
quickly at rest (Fontaine stage II, Rutherford grade I). In more severe cases, pain is present at 
rest (Fontaine stage III, Rutherford grade II). Severe ischemia is evidenced by ulcers and 
gangrene, typically presenting in the distal part of the limb (Fontaine stage IV, Rutherford 
grade III). Critical limb ischemia (CLI) is defined as the presence of ischemic rest pain for more 
than 2 weeks or ischemic skin lesions, either ulcers or gangrene. Acute limb ischemia may occur 
following an embolic event or local thrombosis and has a 10 - 30% 30-day amputation rate. 
(Norgren et al. 2007.) 
The primary test for the diagnosis of LEAD is the ankle-brachial index (ABI), i.e. the ratio of 
ankle and brachial systolic blood pressures (European Stroke Organisation 2011). A value of  
< 0.9, indicative of a hemodynamically-significant arterial stenosis, is 95% sensitive and 99% 
specific for the diagnosis of LEAD (McDermott et al. 2002). Moreover, a reduced ABI has 
prognostic value in identifying persons at risk for suffering cardiovascular morbidity and 
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mortality (Hirsch et al. 2006). A very high ABI (> 1.4) in relation to stiff (calcified) arteries is also 
associated with increased mortality (Criqui et al. 2010). 
The conservative treatment of PAD includes smoking cessation, dietary therapy aiming at 
weight reduction, exercise and pharmacotherapy comprising antiplatelet agents, lipid-lowering 
agents and antihypertensive drugs (European Stroke Organisation 2011). In addition, 
vasodilators such as cilostazol and naftidrofuryl, may have a mild-to-moderate effect to 
improve walking distance in patients with intermittent claudication (Pande et al. 2010, De 
Backer et al. 2009). Revascularization is considered in patients with CLI or severely debilitating 
claudication when the response to conservative therapy has been inadequate (O'Donnell et al. 
2011). Angioplasty is preferred for single short stenoses in the common iliac artery, whereas 
endovascular or open vascular surgery utilizing vein grafts or synthetic prostheses are best 
suited for diffuse occlusive disease (European Stroke Organisation 2011). Bypass surgery 
appears to have a better long-term patency than endovascular interventions, although the risks 
of surgery are greater in terms of mortality rates, major complications and technical success rate 
(European Stroke Organisation 2011, Norgren et al. 2007). Amputation remains the final option 
to resolve irreversible limb ischemia, particularly in the case of infectious gangrene or extensive 
necrosis. One year after the onset of CLI, 25% of patients will have died and 25% will have 
required a major amputation. (Norgren et al. 2007.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Magnetic resonance angiography of a patient with PAD. The double-ended arrow marks the 
superficial femoral artery that is severely stenosed on the right and occluded on the left. Small 
arrows point to collaterals arising from the deep femoral artery. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Cardiology, Lau et al., “Peripheral artery disease. Part 1: 
clinical evaluation and noninvasive diagnosis” © 2011. 
 
2.1.3 Coronary artery disease 
Cardiovascular diseases are the leading cause of death in both high- and low-income countries, 
with 7.2 million people dying of coronary artery disease (CAD) alone in 2002 (WHO 2014). With 
respect to all the cardiovascular diseases, CAD is the most prevalent manifestation with clinical 
presentations including silent ischemia, stable and unstable angina pectoris, myocardial 
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infarction, heart failure and sudden cardiac death (Kumar, Abbas & Fausto 2005). These are 
generally caused by a progressive encroachment of the arterial lumen leading to stenosis or 
acute plaque rupture with thrombosis, with or without concomitant vasoconstriction. A 75% 
reduction in the cross-sectional area of the lumen induces symptoms during exertion, whereas 
an occlusion exceeding 90% leads to insufficient coronary flow at rest. (Kumar, Abbas & Fausto 
2005, Grech 2003.) Primary interventional therapies for coronary insufficiency are percutaneous 
coronary intervention (PCI) and coronary artery bypass grafting (CABG). CABG remains the 
treatment of choice for patients with severe CAD, i.e. those with left main coronary artery 
disease or three-vessel disease. (Levine et al. 2011, Serruys et al. 2009.) For PCI, a focal stenosis 
on a straight artery without involvement of major side branches is ideal (O'Toole, Grech 2003). 
Patients unsuitable for revascularization procedures form a heterogenous group with 
annualized mortality rates ranging from 3% to 21%. Nonsuitability for revascularization may be 
due to anatomical reasons, such as diffuse thread-like coronary atherosclerosis, or non-
anatomical factors including excessive comorbidities, procedural risk and poor compliance to 
medication. (Jolicoeur et al. 2012.) 
 
2.1.4 Lymphedema 
The lymphatic vessels play a key role in the regulation of tissue fluid homeostasis and immune 
functions of the body (Alitalo 2011, Witte, Witte 1987). Blockage of lymphatic drainage due to 
infection, surgery, cancer or a genetic defect leads to lymphedema, which manifests as 
disfiguring and gross swelling of the extremities (Figure 2) (Warren et al. 2007). Edema 
develops as plasma proteins leak into the interstitium raising the colloid osmotic pressure of the 
interstitial fluid, which draws even more fluid out of the capillaries (Guyton, Hall 2006). 
Lymphedema is usually a progressive, chronic condition that is often complicated by recurrent 
lymphangitis, cellulitis, or in rare cases, cutaneous malignant tumors (Szuba, Rockson 1998). In 
the stage I clinical classification of lymphedema, the swelling, which consists of protein-rich 
fluid, is considered to be reversible simply by limb elevation, whereas in stage II, the affected 
tissue hardens as a result of inflammation, fibrosis, adipose tissue hypertrophy and scarring, 
eventually becoming irreversible. Advanced lymphedema (stage III) refers to lymphostatic 
elephantiasis, cartilaginous hardening with hyperkeratosis and papillomatous outgrowths of 
the skin. (International Society of Lymphology 2009.) Lymphedemas are etiologically divided 
into two categories: Primary lymphedemas are caused by rare congenital defects and can 
develop in utero, neonatally, or years or decades after birth, whereas the more common 
secondary lymphedemas are caused by disruption of a normal lymphatic system by disease or 
an iatrogenic process (Warren et al. 2007). Different types of lymphedema, mutated genes 
identified as being involved or other causes, as well as clinical manifestations are listed in table 
1. 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Lymphedema of the lower limbs. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Genetics, Ostergaard et al., “Mutations in GATA2 cause primary lymphedema associated with 
a predisposition to acute myeloid leukemia (Emberger syndrome)”, © 2011. 
 
 
Table 1. Various lymphedema syndromes, their causes or causative mutations and clinical findings. 
 
Disease Cause/Mutation Manifestations 
Lymphedema-distichiasis FOXC2 Lymphedema of lower extremities, double row of eyelashes, additional complications, e.g. ptosis 
Primary congenital 
lymphedema / Nonne-Milroy 
lymphedema 
VEGFR3 Congenital lymphedema of lower limbs 
Milroy-like disease VEGFC Congenital lymphedema of lower limbs 
Hypotrichosis-lymphedema-
telangiectasia syndrome SOX18 Lymphedema, alopecia, telangiectasias 
Meige disease / lymphedema 
praecox GJC2 
Lymphedema affecting all 4 extremities, onset 
typically at <15 years of age 
Hennekam syndrome CCBE1 Lymphedema, intestinal lymphangiectasias, mental retardation, dysmorphic facial features 
Lymphedema-choanal atresia PTPN14 Lymphedema of lower extremities in children, blockage of choanae 
Emberger syndrome GATA2 Lymphedema of lower extremities and genitals, hematological abnormalities, deafness 
MCLMR KIF11 Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation 
Filariasis Parasite infection Lymphedema of lower extremities and genitals 
Cancer-related lymphedema Surgical or radiation therapy of cancer 
Lymphedema of extremities or trunk depending 
on the location, type and treatment of cancer 
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2.1.4.1 Primary lymphedema 
The prevalence of primary lymphedema has been estimated at 1.15 per 100000 persons less than 
20 years of age (Smeltzer, Stickler & Schirger 1985). To date, at least 9 genes responsible for 
different isolated or syndromic forms of primary lymphedema have been identified with the 
help of genetic studies and genetically modified mouse models (table 1). Intriguingly, most of 
the proteins encoded by these genes are linked to the VEGF-C/VEGFR-3 (Vascular endothelial 
growth factor receptor-3) signaling axis. Overall, genetic mutations in 8 specific genes have 
been estimated to account for the etiology of 40% of familial lymphedema and 10% of the 
sporadic occurrences, which together account for less than 25% of patients with lymphedema. 
(Brouillard, Boon & Vikkula 2014, Mendola et al. 2013.)  
The most common form of primary lymphedema is lymphedema-distichiasis (LD), which is 
an autosomal-dominant disorder caused by loss-of-function mutations affecting the forkhead 
transcription factor (FOXC2) (Fang et al. 2000). Transcription factors, such as FOXC2, cause 
syndromic forms of lymphedema by acting downstream of VEGFR-3 and affecting several 
target genes (Brouillard, Boon & Vikkula 2014). LD is characterized by late-onset lymphedema 
of the lower extremities and a congenital double row of eyelashes (distichiasis) occurring in 94-
100% of the patients, with additional complications including varicose veins, ptosis, extradural 
cysts, cardiac defects, and cleft palate. In this disease, lymphedema develops as a result of 
lymph reflux, which is likely due to a primary valve failure. (Connell, Brice & Mortimer 2008.) 
Foxc2-/- mice have been found to exhibit abnormal pericyte recruitment to the lymphatic 
capillaries and valve agenesis in the collecting vessels, indicating that FOXC2 is essential for the 
formation of a pericyte-free lymphatic network and lymphatic valve development (Petrova et 
al. 2004). Moreover, patients with LD experience venous valve failure in addition to 
lymphedema, suggesting a common mechanism for the morphogenesis of venous and 
lymphatic valves (Mellor et al. 2007). Gain-of-function mutations in FOXC2 have also been 
shown to occur in patients with lymphedema, although their association with distichiasis has 
not been confirmed (van Steensel et al. 2009). 
There is another form of hereditary lymphedema called primary congenital lymphedema, 
also known as Nonne-Milroy lymphedema, which is an early-onset congenital lymphedema 
linked to heterozygous missense mutations inactivating the kinase activity of VEGFR3 in about 
70% of cases (Gordon et al. 2013b, Karkkainen et al. 2000). In addition, a homozygous recessive 
mutation in VEGFR3 has been reported in a lymphedema patient (Ghalamkarpour et al. 2009). 
A recent study identified a novel mutation in VEGFC as a cause for Milroy-like primary 
lymphedema (Gordon et al. 2013a). Mutations have been reported in more than 100 families to 
date (Brouillard, Boon & Vikkula 2014). The phenotype of Milroy patients is characterized by 
uni- or bilateral edema of the lower limbs with more infrequent manifestations including 
cellulitis, large calibre leg veins, papillomatosis and upslanting toenails (Brice et al. 2005). 
Lymphatic abnormalities are only present at sites of swelling, and the lymphatic drainage 
routes of the upper limb are normal despite the germline mutation (Connell, Brice & Mortimer 
2008). The vast majority, 90%, of patients with VEGFR3 mutations were found to exhibit 
saphenous vein reflux, regardless of whether lymphedema was present or not, implying a dual 
role of the gene in venous and lymphatic development (Mellor et al. 2010). Contrary to the 
former belief that Nonne-Milroy lymphedema follows from aplasia, skin biopsies from the 
swollen feet of patients with VEGFR3 mutations have revealed the presence of abundant yet 
dysfunctional skin lymphatic vessels, attributing lymphedema rather to the functional failure of 
initial lymphatics than their absence (Mellor et al. 2010). However, knockout mice with similar 
Vegfr3 mutations display hypoplasia of the cutaneous lymphatics due to defective 
lymphangiogenesis, and this condition can be rescued by therapeutic delivery of VEGF-C 
(Karkkainen et al. 2001). 
Hypotrichosis-lymphedema-telangiectasia (HLT) is a very rare syndrome associated with 
mutations in the Sex determining region Y box 18 transcription factor (SOX18), and inherited 
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either autosomal dominantly or autosomal recessively (Irrthum et al. 2003). It is characterized 
by a combination of sparse hair, dilation of small blood vessels particularly in the palms, and 
lymphedema of the legs, which is likely due to lymphatic capillary hypoplasia (Schulte-Merker, 
Sabine & Petrova 2011). SOX18 has been demonstrated to promote lymphatic endothelial cell 
(LEC) differentiation from venous precursors and to act in several developmental systems, 
including hair follicle development, vasculogenesis, and lymphangiogenesis (Francois et al. 
2008).  
Meige disease, also termed lymphedema praecox, manifests as lymphedema in all four 
extremities and it is usually detected at less than 15 years of age, but a causative genetic 
mutation is yet to be confirmed. However, missense mutations in the GJC2 (Gap junction 
protein, gamma 2) gene encoding connexin 47 have been found to alter gap junction function, 
leading to impaired pulsatile lymphatic flow in patients with dominantly inherited 
lymphedema. (Ostergaard et al. 2011a, Ferrell et al. 2010.) Thus, GJC2 is considered as a 
candidate gene to explain the lymphedema of some patients previously labeled as having 
Meige disease (Connell et al. 2013). Hennekam syndrome, which is inherited autosomal 
recessively, comprises lymphedema, intestinal and renal lymphangiectasias, mental retardation 
and dysmorphic facial appearance (Alders et al. 2009). The genetic mutation responsible for 
lymphatic vessel dysplasia in this syndrome is located in CCBE1 (Collagen and calcium binding 
EGF domains 1), which normally potentiates the effects of VEGF-C on VEGFR-3 and has been 
shown to regulate LEC precursor budding and angiogenic sprouting in zebrafish (Jeltsch et al. 
2014, Bos et al. 2011, Alders et al. 2009, Hogan et al. 2009). PTPN14 (Protein tyrosine 
phosphatase, non-receptor type 14) is an intracellular phosphatase that interacts with VEGFR-3 
upon activation by VEGF-C. Ptpn14-deficient mice display postnatal lymphedema due to 
hyperplastic lymphatic vessels. (Au et al. 2010.) A mutation in PTPN14 gene leads to 
lymphedema-choanal atresia syndrome in humans, which is characterized by blockage of nasal 
passage (choana) and lymphedema of the lower extremities in children (Schulte-Merker, Sabine 
& Petrova 2011). Emberger syndrome presents as co-occurring primary lymphedema and 
myelodysplasia progressing to acute myeloid leukaemia, with or without congenital deafness. 
The mutation responsible for lymphedema and predisposition to leukaemia in this syndrome is 
in GATA2 (GATA binding protein 2), which is a transcription factor controlling PROX1 
(Prospero-related homeobox transcription factor 1) and FOXC2 expression. (Brouillard, Boon & 
Vikkula 2014, Ostergaard et al. 2011b.) Mutations in KIF11 (Kinesin family member 11) cause a 
specific syndrome named MCLMR, consisting of microcephaly with or without 
chorioretinopathy, lower limb lymphedema, or mental retardation. A definitive link between 
KIF11 and VEGF-C/VEGFR-3 pathway is yet to be established, but inhibition of EG5, which is a 
kinesin motor protein involved in mitotic spindle assembly and encoded by KIF11, activates a 
downstream signaling pathway of VEGFR-3. (Brouillard, Boon & Vikkula 2014, Ostergaard et 
al. 2012.) In addition, lymphedema occurs in several other syndromes including Turner 
syndrome, Noonan syndrome, and Aagenaes’ syndrome (cholestasis-lymphedema syndrome) 
(Ferrell, Finegold 2008, Loscalzo et al. 2005). 
 
2.1.4.2 Secondary lymphedema 
The most prevalent etiology of acquired lymphedema is filariasis (elephantiasis) secondary to 
Wuchereria bancrofi (~95%), Brugia malay or Brugia timori infection, which is estimated to affect 
120 million people worldwide with 1.2 billion people at risk of infection (Ottesen et al. 2008). 
The mosquito-borne parasitic nematodes reside in the lymphatic system; this triggers an 
inflammatory reaction and activates the production of VEGF-A, VEGF-C and VEGF-D, thus 
leading to hyperplasia and obstruction of the lymphatic vessels usually in the lower extremities 
and genitals (Pfarr et al. 2009). The Global Programme for the Elimination of Lymphatic 
Filariasis is attempting to eliminate the disease as a public health problem by the year 2020, by 
conducting mass drug administrations with the aim of stopping transmission in endemic areas 
(Ottesen et al. 1997). Reductions in infection prevalence and even certified elimination of 
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lymphatic filariasis have been achieved in some isolated areas by the use of microfilaricidal 
drugs, i.e. drugs that kill the first larval stage, the microfilariae (Hoerauf 2008). However, these 
drugs provide no help to already infected individuals, as it is the death of the adult-stage worm 
that causes the pathological changes to occur (Pfarr et al. 2009). Instead, doxycycline has shown 
strong macrofilaricidal activity in affected patients by killing worm symbiotic bacteria 
(Wolbachia), consequently leading to a reduction in plasma concentrations of VEGF-C/sVEGFR-3 
(soluble vascular endothelial growth factor receptor-3), which precedes the amelioration of 
lymphatic vessel dilation and lymphedema (Debrah et al. 2006). 
In the developed countries, the most common cause of secondary lymphedema is surgical or 
radiation therapy of a malignancy, especially breast cancer but also pelvic cancer and malignant 
melanoma (Oremus et al. 2012). Tumor cells often metastasize to lymph nodes, necessitating 
radical surgery with lymph node dissection and adjuvant radiotherapy, which damage the 
collecting lymphatic vessels and impair lymphatic flow (Norrmen et al. 2011). The remaining 
lymphatic vessels need to distend to accommodate the increased fluid load. Collecting 
lymphatic vessels may regenerate and spontaneously recanalize to some extent, but typically an 
adequate formation of new lymphatic vessels is not observed in lymphedema patients. (Tobbia 
et al. 2009, Ikomi et al. 2006, Abe 1976.) The pathophysiology of breast cancer-related 
lymphedema is not yet fully understood. The traditional view is the so-called stopcock 
hypothesis, according to which the surgically traumatized axilla impairs the lymphatic drainage 
from the entire arm, as if a stopcock had been partially closed. It does not, however, explain the 
delayed onset of swelling, the non-uniform distribution of swelling along the arm, sparing of 
some regions, e.g. the hand, and the lowering of plasma protein levels in the affected arm. 
(Stanton et al. 2009b.) The edema mainly accumulates in the highly compliant subcutis and skin, 
whereas there is very little swelling observed in the muscle compartment (Collins et al. 1995). 
The literature does not provide reliable prevalence rates, although there is an estimate that 
there are 10 million patients suffering from secondary lymphedema in the US alone (Szuba et al. 
2003). The incidence of upper-limb lymphedema following mastectomy ranges between 24% 
and 49%, with lower rates of 4 - 28% reported for lumpectomy, although there has been a 
reduction in the reported incidence since the development of lymphatic mapping and sentinel 
lymph node biopsy to assess metastatic spread of cancer (DiSipio et al. 2013, Warren et al. 2007). 
Approximately 75% of breast cancer-related lymphedema cases develop within 2 years of 
surgery and 90% within 3 years, but it can remain latent for as long as 20 years (Stanton et al. 
2009b). Risk factors for developing post-mastectomy lymphedema include the extent of axillary 
surgery, adjunctive radiotherapy, postoperative seroma, obesity, infection or trauma to the 
ipsilateral limb, and most novelly, a high peripheral blood vascular filtration rate, i.e. higher 
demand for lymphatic drainage (Stanton et al. 2009a, Warren et al. 2007, Herd-Smith et al. 
2001). Recently, a genetic predisposition has been implicated in the development of 
lymphedema following breast cancer treatment (Newman et al. 2012, Finegold et al. 2012). 
Acquired lymphedema can also be secondary to peripheral arterial disease, varicose vein 
surgery, saphenous vein harvesting for bypass surgery, circumcision, intrathecal pump 
insertion for analgesia, recurrent bacterial lymphangitis, burns, and the spread of malignant 
tumors obstructing the lymphatics or regional lymph nodes (Rockson, Rivera 2008). 
There is currently a paucity of effective treatment strategies for lymphedema. The availabe 
therapy is based on conservative methods, e.g. compression garments, manual lymphatic 
drainage (MLD) and complex decongestive therapy (MLD, limb compression, skin care and 
exercise combined), or mechanical treatments such as intermittent pneumatic compression 
devices and low-level laser therapy, or occasionally surgery. In addition, pharmacological 
therapy in the form of benzopyrones has been attempted, as benzopyrones are thought to 
increase proteolysis in the edematous tissue. (Warren et al. 2007.) Problems associated with 
conservative treatments are minor, and they are likely to have little impact on the clinical 
outcome (Oremus et al. 2012). Surgical approaches, including resection procedures, 
microsurgical interventions and liposuction, are considered when lymphedema is refractory to 
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non-operative treatment. Resection surgery involves the excision of subcutaneous tissue, and it 
is applied in extreme cases, when massive limb changes or fibrotic induration are observed. 
(Murdaca et al. 2012.) These ‘debulking’ operations may, however, result in extensive scar 
formation and substantial morbidities of the skin, including ulceration, keloids and 
papillomatosis (Warren et al. 2007). Circumferential liposuction combined with lifelong 
compression, on the other hand, is a minimally invasive, novel technique to remove the 
hypertrophied adipose tissue and it is claimed to achieve a consequential improvement in skin 
microcirculation, reduced cellulitis, and a significant reduction of edema with no recurrence 
during 7 years’ follow-up (Damstra et al. 2009, Brorson 2003). Microsurgical techniques, 
creating lymphaticovenous or lymphaticolymphatic anastomoses in order to directly correct the 
underlying pathology, appear to promote the long-term alleviation of edema (Felmerer et al. 
2012, Campisi, Boccardo 2004, Baumeister, Siuda 1990). Although no consensus prevails with 
regard to what is the optimal surgical method, a minimally invasive lymphovenous shunt 
operation utilizing microsurgical techniques is the most popular at present (Suami, Chang 
2010). Overall, surgical treatment modalities have met with limited success due to the 
difficulties in identifying, preserving and anastomosing lymphatic vessels to pre-existing 
networks (Saaristo et al. 2012). 
Microvascular lymph node transfer, a technique in which composite soft tissue including 
lymph nodes is transplanted to the axilla or wrist of the lymphedematous limb, has been 
reported to decrease perimeter and improve lymph drainage in the affected arm (Lin et al. 2009, 
Becker et al. 2006). Lymph node transfer has also been combined with standard breast 
reconstruction surgery in the simultaneous reconstruction of the missing breast and lymphatic 
network in the operated axilla (Saaristo et al. 2012). However, in microvascular lymph node 
transfer, new lymphatic vessels are believed to sprout spontaneously from the transferred 
lymph nodes and form anastomoses with the recipient site (Suami, Chang 2010). It is essential 
that there is a viable connection with lymphatic vessels for the viability and function of the 
lymph nodes, and experimental studies have shown that incorporation of the lymph nodes into 
the existing lymphatic vasculature may fail, resulting in a deterioration of the transferred lymph 
node (Hadamitzky, Blum & Pabst 2009, Tammela et al. 2007, Mebius et al. 1991). Therefore, the 
combination of surgical lymph node transfer with simultaneous administration of pro-
lymphangiogenic growth factors may promote the reconstruction of the lymphatic vasculature 
and alleviate postoperative lymphedema. This approach will be further reviewed in chapter 
2.6.1 “Preclinical studies of lymphedema”. 
 
2.1.5 Tumor lymphangiogenesis and metastasis 
The lymphatic vasculature serves as a conduit for tumor cells, as they spread via lymphatic 
vessels to colonize lymph nodes. In some respects, tumor cells resemble leukocytes by 
exploiting many of the same trafficking pathways, chemokines, and adhesion molecules to gain 
access to lymphatic vessels. (Holopainen et al. 2011, Muller et al. 2001.) Several cancers, breast 
cancer and melanoma in particular, are known to metastasize to lymph nodes; this often 
determines their prognosis and predicts patient survival. The metastatic status of lymph nodes 
has an important role in tumor staging and clinical decision-making. (Sleeman, Thiele 2009, 
Scoggings et al. 2005.) Many tumors and tumor-associated macrophages express two 
lymphangiogenic growth factors, VEGF-C and VEGF-D, and this property has been shown to 
correlate with tumor-associated lymphangiogenesis, lymphatic invasion, distant metastasis, and 
poor clinical outcomes (Holopainen et al. 2011). Interestingly, lymphangiogenesis has also been 
reported to occur in sentinel lymph nodes even prior to the arrival of metastatic tumor cells, as 
well as in metastatically non-involved, remote lymph nodes, indicating that primary tumors 
prepare their future metastatic site in advance by producing sufficient concentrations of 
lymphangiogenic growth factors to induce lymphatic vessel growth in the target tissue 
(Hirakawa et al. 2007, Van den Eynden et al. 2006). Antilymphangiogenic strategies using 
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neutralizing antibodies against VEGFR-3, the neuropilin 2 (NRP2) co-receptor, VEGF-C, and 
VEGF-D, as well as soluble VEGFR-3 fusion proteins, have been employed in the battle against 
tumor lymphangiogenesis and metastasis, and a VEGFR-3-targeting monoclonal antibody has 
entered phase 1 clinical trials (Alitalo 2011). Blocking of VEGFR-3 exerts no effect on pre-
existing vessels, but leads to inhibition of lymphatic vessel growth in tumors and thus has 
achieved a reduction of lymph node metastases in preclinical animal models (Karpanen et al. 
2006b, Lin et al. 2005, He et al. 2005). The involvement of lymphangiogenic growth factors in 
tumor progression and metastasis is an important consideration regarding the safety of pro-
lymphangiogenic gene therapy, and will be further discussed in chapter 2.5.3 “Safety issues in 
gene therapy”.  
 
2.1.6 Other lymphatic vasculature-associated diseases 
Lymphatic hyperplasia or enhanced lymphangiogenesis have been associated with chronic 
inflammation in psoriasis, colitis ulcerosa, rheumatoid arthritis, Mycoplasma pulmonis infection 
and kidney transplant rejection (Cueni, Detmar 2008). Recent research has shed light into the 
molecular mechanisms behind inflammation-induced lymphangiogenesis, suggesting that 
induction of the NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells) 
pathway by inflammatory stimuli promotes VEGFR-3 expression in LECs, thus leading to 
increased sensitivity of the pre-existing lymphatics to VEGF-C and VEGF-D and enhanced 
lymphangiogenesis (Flister et al. 2010). At sites of tissue inflammation, macrophages contribute 
to lymphatic vessel growth by producing VEGF-C and VEGF-D, and furthermore, they have 
been reported to transdifferentiate into LECs in inflamed mouse cornea (Maruyama et al. 2005, 
Cursiefen et al. 2004). In addition, VEGF-A appears to have a role in inflammation-induced 
lymphangiogenesis, as it was found to induce leaky, functionally impaired lymphatic vessels in 
the murine epidermis after ultraviolet B-irradiation, and this could be prevented by 
administration of a VEGF-A neutralizing antibody (Kajiya, Hirakawa & Detmar 2006). VEGF-A-
mediated inflammatory lymphangiogenesis may be the result of VEGF-A’s chemotactic 
recruitment of macrophages, which in turn supply VEGF-C and -D (Cursiefen et al. 2004). 
Enhanced lymphangiogenesis in inflammatory conditions facilitates the resolution of edema 
and inflammatory infiltrate, making stimulation of lymphangiogenesis an attractive treatment 
option for certain inflammatory conditions (Cueni, Detmar 2008). In contrast, blockade of 
VEGFR-3 signaling has been reported to suppress dendritic cell migration and concomitant 
corneal transplant rejection in mice, as well as adaptive immune responses towards heart 
transplants in a rat model, which may be evidence in favor of inhibition of lymphangiogenesis 
in the context of heterologous tissue transplantation (Alitalo 2011, Nykanen et al. 2010, Chen et 
al. 2004). 
Lymphatic dysfunction has been proposed to be connected to disturbances in lipid 
homeostasis, as patients with chronic lymphedema gradually accumulate subcutaneous fat in 
edematous sites (Dixon 2010a). Similar observations have been made in mice with secondary 
lymphedema, where impaired lymphatic drainage led to abnormal lipid accumulation that 
persisted even after the lymphatic drainage was restored (Rutkowski et al. 2006). In Prox1+/- 
mice, abnormal leakage of lymph from mesenteric lymphatic vessels appears to promote lipid 
accumulation, and these mice also possess higher levels of leptin and fatty livers, which are 
features of late-onset obesity in humans (Harvey et al. 2005). The role of lymphatic vessels in 
atherosclerosis remains as yet undefined, although increased lymphangiogenesis has been 
observed in progressive atherosclerotic lesions and stenotic aortic valves (Syvaranta et al. 2012, 
Kholova et al. 2011). Lymphatic vessels are rare in the intima and abundant in the adventitia of 
atherosclerotic coronary arteries, but the functional consequences of lymphangiogenesis in the 
adventitia are unknown (Nakano et al. 2005). ApoE-/- (Apolipoprotein E) mice display not only 
tertiary lymphoid organs in the adventitia of aortas but also degeneration and loss of function 
of lymphatic vessels in response to hypercholesterolemia (Lim et al. 2009, Grabner et al. 2009). 
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Altogether, it has been proposed that a compromised lymphatic system may contribute to the 
increased plasma cholesterol levels and the accumulation of cholesterol and inflammatory cells 
in atherosclerotic lesions (Vuorio et al. 2014, Syvaranta et al. 2012, Lim et al. 2009). However, 
VEGF-C and VEGF-D were shown to exert neither anti- nor pro-atherogenic effects in a mouse 
model of atherosclerosis (Leppanen et al. 2005). Lymphatic vessels were recently found to play 
a significant role in reverse cholesterol transport (RCT), which is involved in the removal of 
excess cholesterol from peripheral tissues (Lim et al. 2013, Martel et al. 2013). Mice transplanted 
with atherosclerotic aortas displayed impaired RCT when lymphatic drainage was blocked 
(Martel et al. 2013). Conversely, VEGF-C treatment to restore lymphatic function improved RCT 
(Lim et al. 2013). 
LECs give rise to various lymphovascular tumors, such as lymphangiosarcoma, which is a 
rare malignant tumor reported in the context of chronic lymphedema due to mastectomy, 
inguinal lymphadenectomy, trauma, or infection (Krishnamoorthy et al. 2012). 
Lymphangioleiomyomatosis (LAM), on the other hand, is a benign neoplasm affecting young 
females that is characterized by the proliferation of SMC-like cells and lymphatic vessels, as 
well as pulmonary cysts that impair lung function over time, finally resulting in respiratory 
failure. LAM cells secrete high levels of VEGF-D and spread through the lymphatic vessels to 
distant sites, where they may disrupt lymphatic function. (Seyama et al. 2010.) Kaposi sarcoma, 
caused by the Kaposi sarcoma herpesvirus (KSHV), is an angiogenic tumor predominantly seen 
in people with acquired immunodeficiencies. Kaposi sarcoma cells express both blood 
endothelial and LEC markers, and VEGFR-3 antibody treatment has been claimed to be 
effective in reducing lymphangiogenic sprouting of KSHV-infected LECs in three-dimensional 
culture. (Alitalo 2011, Tvorogov et al. 2010.) 
Interstitial lymphangiogenesis due to increased production of VEGF-C by macrophages has 
been linked to extrarenal maintenance of normal blood pressure in conditions of interstitial salt 
accumulation in the skin. Blockade of VEGF-C signaling has led to salt-induced hypertension in 
rats, suggesting that the immune system regulates volume and blood pressure homeostasis via 
lymphangiogenic growth factor activation. (Machnik et al. 2009.) Furthermore, lymphatic vessel 
dysfunction has been implicated in the failure of neonatal lung inflation (Jakus et al. 2014). 
2.2 THE BLOOD VASCULAR SYSTEM AND BLOOD VESSEL GROWTH 
2.2.1 Structure and function of the blood vascular system 
The blood vascular system exists to deliver oxygen, nutrients and hormones to the tissues, as 
well as to remove carbon dioxide and metabolic waste products from the tissues (Guyton, Hall 
2006). The vascular system is the first organ system to develop in the embryo, and a failure to 
establish a functional circulation leads to death during early organogenesis (Copp 1995). The 
cardiovascular system comprises the heart, which is responsible for circulating blood; the 
arteries and veins which transport blood to and from the peripheral tissues; and the capillaries, 
which allow the diffusion of substances between the blood and the surrounding tissues. The 
rate of blood flow is regulated intrinsically by tissues and organs to meet their metabolic and 
functional needs, as well as extrinsically via neural or hormonal influences. Ultimately, it is the 
balance between these regulatory mechanisms that determines the vascular tone and blood flow 
in the tissue. (Guyton, Hall 2006.) 
The heart pumps blood first through large elastic arteries such as the aorta, subclavian, and 
iliac arteries, which then branch into medium-sized muscular arteries and subsequently into 
small arteries and arterioles, which are the main regulators of physiologic resistance to blood 
flow (Kumar, Abbas & Fausto 2005). Capillaries originate from the point of metarteriole-
capillary junctions, where precapillary sphincters act as shunts by opening and closing the 
entrance to the capillaries based on local O2 (oxygen) concentrations (Guyton, Hall 2006). The 
capillaries with their thin walls as well as the pores in their walls when combined with the tiny 
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diameter of a single erythrocyte and slow flow, create the ideal conditions for the exchange of 
fluid, nutrients, electrolytes and hormones between the blood and the interstitial fluid (Kumar, 
Abbas & Fausto 2005). Filtration of fluid in and out of the capillaries is powered by hydrostatic 
pressure forcing fluid out of the arterial side of the capillary bed, and colloid osmotic pressure 
causing reabsorption of extravasated fluid into the venous side of the capillary bed (Guyton, 
Hall 2006). The capillaries are located within 200 μm of any cell, except in avascular tissues such 
as cartilage and cornea of the eye, and they are highest in density in metabolically active tissues, 
such as the myocardium (Kumar, Abbas & Fausto 2005, Carmeliet, Jain 2000). The O2-deprived 
blood flows from the capillaries into postcapillary venules, which are the main site of vascular 
leakage and leukocyte infiltration in inflammatory reactions. The larger veins, which are 
formed progressively from mergers of venules, transport the blood back to the heart at a slower 
rate and under lower pressure conditions than those prevailing in the arterial system. Venous 
valves and surrounding skeletal muscle contractions augment blood flow particularly in the 
extremities to overcome gravity and prevent reverse flow. The veins are able to retain large 
quantities of blood: approximately 66% of all blood is in the veins at any given time. (Guyton, 
Hall 2006, Kumar, Abbas & Fausto 2005.) 
 
2.2.2 Blood vessel components 
The main constituents of blood vessel walls are endothelial cells (ECs), SMCs, and extracellular 
matrix, including elastin, collagen and glycosaminoglycans. Three layers - intima, media, and 
adventitia - separated by the internal and external laminas, can be defined in arteries and veins, 
although the proportions of these layers vary dramatically between these two vessel types. In 
comparison to veins, arteries have thicker SMC layers of media, and round, open lumens even 
when not filled with blood. In contrast, veins display larger diameters and lumens, as well as 
thinner media but thicker adventitia to protect them from external trauma. (Kumar, Abbas & 
Fausto 2005.) The Notch signaling pathway controls the commitment of angioblasts to arterial 
or venous lineages in the embryo before the appearance of the circulation, but arterial-venous 
differentiation is also driven by hemodynamic forces (le Noble et al. 2004, Lawson, Vogel & 
Weinstein 2002). Vascular cells display a high degree of plasticity with respect to environmental 
factors, and the predetermined identity can be remolded even in the adult (Fann et al. 1990). 
Capillary walls consist of merely a monolayer of ECs adjoined by different types of 
intercellular junctions, such as tight junctions or the more dynamic adherens junctions, which 
control endothelial permeability (Dejana, Corada & Lampugnani 1995). ECs play a central role 
in vascular biology and pathology, particularly in vasotonus modulation, blood-tissue 
interactions, fibrinolysis and coagulation, blood cell activation and migration, and the 
vascularization of normal and neoplastic tissues. The microvascular endothelium exhibits 
different phenotypes based on anatomic location and adaptation to environment. For example, 
the endothelium in the central nervous system, which is a part of the blood-brain barrier, is 
continuous with complex tight junctions and allows only selective movement of molecules 
across, whereas the fenestrated endothelium promotes a high rate of absorption in the 
gastrointestinal tract and secretion in the endocrine glands. (Risau 1995.) Lymph nodes contain 
special postcapillary venules called high endothelial venules in reference to their plump 
phenotype, which permit lymphocyte entry from the blood circulation to the lymph node 
(Girard, Springer 1995). Endothelial activation happens in response to various 
pathophysiological stimuli, e.g. there are inducers such as cytokines, bacterial products or 
hemodynamic stresses which activate ECs to express adhesion molecules, and to produce other 
cytokines, chemokines, growth factors and vasoactive molecules (Kumar, Abbas & Fausto 2005). 
Endothelial dysfunction is characterized by impaired vasoreactivity and an abnormally 
thrombogenic and proinflammatory endothelial surface; these pathological changes are 
associated with atherosclerosis, thrombus formation, and cardiovascular diseases in general 
(Endemann, Schiffrin 2004). The EC layer of capillaries, excluding the discontinuous 
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endothelium type found in the liver, spleen and bone marrow, is lined abluminally by a 
basement membrane (BM) and encircled by microvascular pericytes embedded in the 
membrane (Hirschi, D'Amore 1996, Risau 1995). Pericytes are multipotent mesenchymal cells 
that make specific focal contacts with ECs and play a role in vascular growth, stabilization and 
remodeling, as well as in the regulation of capillary blood flow (Armulik, Abramsson & 
Betsholtz 2005). 
 
2.2.3 Vasculogenesis 
The development of the vascular system occurs via two processes, vasculogenesis and 
angiogenesis (Figure 3A). Vasculogenesis is the first step in the formation of the embryonic 
cardiovascular system, involving the de novo differentiation of blood vessels from vascular stem 
cells. EC lineages as well as hematopoietic cells arise from mesoderm-derived stem cells. These 
precursors, called hemangioblasts, form blood islands, in which the centrally located cells 
differentiate into hematopoietic stem cells, whereas the peripheral cells develop into angioblasts 
that further differentiate into vessel wall components, i.e. ECs and mural cells. (Risau, Flamme 
1995.) The blood islands fuse to form a primary capillary plexus, which then undergoes 
complex remodeling to generate the mature vasculature (Coultas, Chawengsaksophak & 
Rossant 2005). Organs developing from the mesoderm and endoderm, e.g. liver, spleen and 
myocardium, are vascularized by vasculogenesis, whereas organs that are not initially 
colonized by angioblasts, e.g. the brain and the spinal cord, develop their vasculature via 
angiogenesis (Kassmeyer et al. 2009). The genetic control of normal vascular development 
includes activation of fibroblast growth factor-2 (FGF-2) to induce production of vascular 
progenitors, as well as VEGF signaling that plays a decisive role in the further development of 
the vascular system (Coultas, Chawengsaksophak & Rossant 2005, Risau, Flamme 1995). 
The default state of the adult vasculature is quiescence, i.e. physiological formation of new 
blood vessels is rare, except in cases of EC proliferation during the estrus cycle or in exercise-
induced muscular hyperplasia (Gielen, Schuler & Adams 2010, Reynolds, Killilea & Redmer 
1992). Neovascularization of this kind occurs primarily via angiogenesis, which was long 
believed to be the only mechanism by which new vessels could be formed in adults. However, 
the term postnatal vasculogenesis has emerged; this refers to de novo recruitment of bone 
marrow-derived endothelial progenitor cells (BM-EPCs) and circulating EPCs for blood vessel 
formation in adults. (Eguchi, Masuda & Asahara 2007, Kopp, Ramos & Rafii 2006.) EPCs are 
believed to migrate, proliferate and differentiate into ECs at their destined location (Kassmeyer 
et al. 2009). In the late 1990s, EPCs were isolated from peripheral blood and shown to be 
recruited at sites of ischemia, thus implying that they would be capable of promoting 
vasculogenesis (Asahara et al. 1997). Since their discovery, it has been observed that the EPC 
population actually consists of several different species of endothelial progenitors with varying 
phenotypic profiles and biological functions (Zampetaki, Kirton & Xu 2008, Lin et al. 2000). 
Subsequently, EPCs have been shown to contribute to blood vessel development in wound 
healing and in tumor growth, as well as to re-endothelialization of injured vessels and vascular 
prostheses (Kassmeyer et al. 2009, Ranjan et al. 2009, Xiao et al. 2006). Low levels of EPCs 
appear to predict the likelihood of major cardiovascular events and to promote the progression 
of atherosclerosis (Fadini et al. 2010, Werner et al. 2005, Hill et al. 2003). Over the years, 
contradictory findings regarding the physiological relevance of EPCs in postnatal 
neovascularization have emerged, and it has been proposed that EPCs do not actually 
proliferate and differentiate into ECs, but derive from mononuclear cells and induce neovessel 
growth indirectly by secreting growth factors (Larrivee, Karsan 2007, Kinnaird et al. 2004, 
Rehman et al. 2003).  
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2.2.4 Angiogenesis 
Angiogenesis is the mechanism by which embryonic organs that are not initially colonized by 
angioblasts, e.g. the brain and the spinal cord, develop a vasculature, as well as the principal 
mechanism of blood vessel growth in adults (Risau 1997, Baldwin 1996). Furthermore, 
pathological angiogenesis is a prerequisite for tumor growth beyond 1-2 mm in diameter and 
the concept of treating tumors by inhibiting angiogenesis was first postulated in the 1970s 
(Folkman 1971). Tumor vessels are irregular and immature with increased leakiness and 
susceptibility to thrombosis and rupture (Carmeliet, Jain 2011). Conversely, insufficient vessel 
growth and regression contribute to disorders like myocardial infarction, stroke, 
and neurodegeneration (Potente, Gerhardt & Carmeliet 2011). Angiogenesis can occur by 
sprouting from pre-existing capillaries, which comprises proliferation, migration, three-
dimensional organization and tube formation of ECs, or by intussusception, in which 
transluminal pillars are formed within capillaries and divide the vessel lumen into two parallel 
vessels, or by bridging, where the vessels split to form daughter vessels via the formation of EC 
bridges (Figure 3A) (Kassmeyer et al. 2009, Burri, Djonov 2002, Conway, Collen & Carmeliet 
2001). 
‘The angiogenic switch’ is a widely accepted term used to describe the balance between the 
inducers of angiogenesis and the countervailing inhibitors: the ‘switch’ is ‘off’ when the 
proangiogenic molecule concentration is balanced by that of the antiangiogenic molecules, and 
‘on’ when the balance shifts towards a proangiogenic state (Bergers, Benjamin 2003). Hypoxia, 
low pH, hypoglycemia, mechanical stress, inflammatory conditions, and malignancies are all 
triggering events of the switch (Carmeliet, Jain 2000). Tissue hypoxia is the main physiological 
stimulus for angiogenesis, leading to increased expression of proangiogenic growth factors, 
most importantly VEGF-A, via activation of the hypoxia-inducible factor, HIF (Hickey, Simon 
2006). After the release of growth factors, a cascade of events takes place in order for vascular 
sprouting to occur: the pre-existing vessels become dilated and hyperpermeable in response to 
nitric oxide (NO) and VEGF-A respectively, the extracellular matrix is remodeled and the BM 
degraded, plasma proteins leak from the angiogenic vessels and serve as a provisional matrix, 
activated ECs proliferate and migrate towards the growth factor gradient, a capillary tube is 
formed, and finally, the sprouts anastomose to form a functional loop, thereby establishing a 
perfusing vessel (Jain 2003). The immature vessel network is then remodeled and pruned by 
tissue-derived signaling molecules and blood flow conditions, e.g. pressure and wall-shear 
stress, to adequately oxygenate the perfused organ (Wacker, Gerhardt 2011, Resnick et al. 2003). 
In order to achieve vessel stabilization and maturation, pericyte coverage is acquired and the 
BM is formed (Jain 2003). ECs with three distinct phenotypes have been described for the 
different roles in vessel branching: non-proliferative, filopodia-rich ’tip cells’ respond to 
environmental cues and lead the way for the growing vessel, ‘stalk cells’ follow behind 
elongating the sprout, and ‘phalanx cells’ are responsible for vessel maturation and stabilization 
(Figure 3B) (De Smet et al. 2009). Tip cells share similar features with the axon growth cone 
guiding neuronal growth, and they both respond to signals from some of the same molecular 
families, such as Slits, Netrins, Semaphorins, and Eph receptors and their ephrin ligands 
(Adams, Eichmann 2010). In contrast to sprouting, intussusception does not require cell 
proliferation and BM degradation, and is usually driven by higher levels of shear stress rather 
than angiogenic factors (Styp-Rekowska et al. 2011).    
Although VEGF-A is the most important driver of vascular formation, other growth factors 
are involved in the process as well. Angiopoietin 1 (ANG1) and ephrin-B2 are required for 
further remodelling and maturation of the immature vasculature. Ephrin-B2 has a crucial role in 
distinguishing arterial and venous identity of developing vessels. (Yancopoulos et al. 2000.) 
Platelet-derived growth factor B (PDGF-B) mediates pericyte differentiation and migration in 
the maturation process of vessels (Lindahl et al. 1997). FGFs are able to initiate angiogenesis, 
where they act not only on ECs but also on other cell types (Hanahan, Folkman 1996). 
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Extracellular edema due to increased vascular permeability is strictly associated with 
angiogenesis, and it can be encountered during proangiogenic gene therapy as a potentially 
serious side effect (Rissanen et al. 2003b, Dvorak et al. 1995). The development of edema in 
skeletal muscle, for example, may worsen ischemia by physically compressing blood vessels. 
An attempt to limit tissue edema by inducing lymphatic vessel growth simultaneously with 
angiogenesis resulted in reduced edema in rabbit skeletal muscles (Lähteenvuo 2009). Thus, a 
combination of proangiogenic and prolymphangiogenic gene therapy may confer added benefit 
in comparison to angiogenic monotherapy alone.   
 
2.2.5 Arteriogenesis 
Arteriogenesis denotes the postnatal remodeling of small arterioles into larger caliber 
conducting arteries (Schaper, Scholz 2003). This process is known to occur in ischemic 
conditions, when gradually developing stenoses stimulate the outgrowth of pre-existing 
collateral arteries to circumvent the arterial occlusion (Figure 3C) (Troidl, Schaper 2012). 
Arteriogenesis takes place in the vicinity of the occluded artery, as opposed to the angiogenic 
response to ischemia, which occurs relatively far and downstream from the occlusion (Schaper, 
Scholz 2003, Ito et al. 1997). The key forces driving arteriogenesis are fluid shear stress acting on 
the endothelium, and circumferential wall stress caused by the tramsmural pressure gradient 
across the vessel wall (Schaper, Scholz 2003, Price et al. 2002). When an arterial occlusion 
develops, a pressure gradient is created between the high-pressure area upstream of the 
occlusion and the low-pressure downstream area. In order for arteriogenesis to successfully 
restore circulation to the affected area, an interconnecting arteriolar network between the 
preocclusive and the postocclusive microcirculation must exist. (Heil, Schaper 2004.) The 
formation of a pressure gradient is followed by a redistribution of perfusion, an increase in 
flow, and consequently, an increase in fluid shear stress, which activates the endothelium 
(Persson, Buschmann 2011). The ECs swell and genes coding for chemoattractant cytokines, 
growth factors, and adhesion molecules are upregulated (Lee et al. 2004, Deindl et al. 2003, 
Schaper et al. 1976). This attracts monocytes to adhere to the endothelium, which then mature 
into macrophages and these cells begin to remodel the vascular wall by secreting proteases 
(Bergmann et al. 2006). Mitosis of ECs and SMCs follows, the neo-intima develops, and a 
collateral artery with a typical corkscrew-like morphology is formed (Scholz et al. 2000). 
Collateral growth is terminated early when the maximal conductance has reached 35 - 40% of 
normal, because the fluid shear stress decreases due to collateral diameter enlargement (Hoefer 
et al. 2001). A few large vessels mature and smaller vessels are pruned in the course of 
establishing an effective collateral circulation, as small vessels have high resistance and vascular 
adaptation always aims at the most economical solution (Troidl, Schaper 2012). Significant 
variation in the ability to grow collateral vessels has been observed between individuals 
(Rehman 2008). A minority (20 - 25%) of patients with functional collaterals seem to be able to 
prevent myocardial ischemia completely during coronary occlusion, which indicates that some 
people may possess a genetic predisposition that favors adaptive collateral growth (Wustmann 
et al. 2003).  
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Figure 3. Schematic representation of the mechanisms of vessel formation. A, Endothelial-cell 
precursors (angioblasts and hemangioblasts) differentiate into ECs which coalesce to form primitive 
vasculogenic networks (vasculogenesis). These networks are remodeled through angiogenic 
processes involving sprouting, intussusception and bridging. Adapted by permission from Macmillan 
Publishers Ltd: Nat Rev Cancer, Hendrix et al., “Vasculogenic mimicry and tumour-cell plasticity: 
lessons from melanoma” © 2003. B, Tip cells lead the way for a growing vessel with stalk cells 
following behind, while phalanx cells are involved in vessel maturation. Adapted with permission 
from Wolters Kluwer Health: Arterioscler Thromb Vasc Biol., De Smet et al., “Mechanisms of Vessel 
Branching: Filopodia on Endothelial Tip Cells Lead the Way, 2009. C, Arteriogenesis occurs in 
response to gradually developing occlusion of an artery to resolve ischemia of the target tissue. 
Adapted from Integr Biol (Camb)., Korpisalo & Ylä-Herttuala, “Stimulation of functional vessel 
growth by gene therapy” (2010), with permission of The Royal Society of Chemistry 
(http://dx.doi.org/10.1039/b921869f). 
 
2.3 THE LYMPHATIC SYSTEM AND LYMPHATIC VESSEL GROWTH 
2.3.1 Anatomy and function of the lymphatic system 
The lymphatic system consists of lymph that is a protein-rich fluid derived from plasma, 
lymphatic vessels that transport lymph, lymphoid cells, and organized lymphoid tissues, i.e. 
lymph nodes, spleen, thymus, tonsils, Peyer’s patches in the intestine, as well as lymphoid 
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tissue in the liver and lungs (Szuba et al. 2003). Lymphatics are dispersed throughout the body, 
particularly at sites that come into direct contact with the external environment, but are absent 
from avascular tissues such as epithelia and cartilage, as well as from the central nervous 
system and bone marrow (Tammela, Alitalo 2010, Drake, Vogl & Mitchell 2005). The lymphatic 
system parallels and supplements the cardiovascular system, but differs from it in several 
aspects. In contrast to the blood vasculature, the lymphatic system is not a circulatory system 
but a one-way transport system. (Norrmen et al. 2011.) Blind-ended lymphatic capillaries 
absorb excess fluid containing pathogens, certain leukocytes, hormones, and cell debris, from 
the interstitial space (Alitalo 2011, Drake, Vogl & Mitchell 2005). Lymph is conveyed to 
progressively larger lymphatic vessels, first to precollectors which then coalesce into collecting 
lymphatic vessels, ultimately to be returned back to the systemic circulation at the 
lymphaticovenous junctions between the thoracic or right lymphatic duct and the subclavian 
veins (Norrmen et al. 2011). The thoracic duct drains the left side of the body, abdomen, lower 
limbs, left arm and shoulder, and the left side of the head and neck, whereas lymph from the 
upper right quadrant of the body wall, right upper limb, and the right side of the head and neck 
is collected into the right lymphatic duct (Drake, Vogl & Mitchell 2005, Jeltsch et al. 2003). The 
overall lymph flow in humans has been estimated to range between 2 and 8 liters per day 
(Levick, Michel 2010, Guyton, Hall 2006). Lymph nodes are located along the course of the 
larger lymphatic vessels; the lymph passes through these nodes before entering the venous 
system. In the lymph nodes, the lymph is screened for pathogens and activated immune cells 
and antibodies are released into the general circulation. (Young et al. 2006.) Thus the lymphatic 
system also plays an integral role in immune responses of the body by serving as a trafficking 
route for immune cells. Specialized lymphatic vessels called lacteals inside the intestinal villi 
absorb dietary fats and fat-soluble vitamins and transport them to the venous circulation (Dixon 
2010b). 
The lymphatic system of the extremities is divided into a superficial (epifascial) compartment 
that drains lymph from the skin and subcutis, and a deeper (subfascial) compartment that 
drains muscle, bone and the deeper blood vessels. These two systems fuse in the pelvic area, 
whereas those of the upper limb merge in the axilla. (Szuba et al. 2003.) In cases of obstruction, 
the epifascial and subfascial compartments can function in an interdependent manner such that 
the healthy compartment is able to compensate for the obstructed counterpart by accelerating 
transport (Brautigam et al. 1998). In normal conditions, subfascial drainage is slower than the 
epifascial form (Mostbeck, Partsch 1999, Brautigam et al. 1998). 
Microstructurally lymphatic capillaries are composed of a monolayer of oak-leaf-shaped 
LECs that are connected by discontinuous button-like junctions, have little to no BM, and lack 
pericytes and SMCs (Schulte-Merker, Sabine & Petrova 2011). Fluid and leukocyte entry is 
enabled by a discontinuous BM containing portals that facilitate cell migration into the vessel, 
and by the presence of specialized flap-like openings between LECs that function as primary 
valves (Pflicke, Sixt 2009, Baluk et al. 2007, Trzewik et al. 2001). LECs are attached to 
extracellular matrix by elastic anchoring filaments, which prevent collapse of the capillary 
should there be an increase in interstitial pressure (Leak, Burke 1968). In contrast to the 
lymphatic capillaries, the LECs of the collecting lymphatic vessels are connected by continuous 
zipper-like junctions and ensheathed by a SMC layer as well as a BM (Tammela et al. 2007). 
Lymphangions, i.e. the functional units of the collecting lymphatic vessels, are separated by 
intraluminal valves, which are particularly numerous per vessel segment in organs with high 
hydrostatic pressure, such as legs (Schulte-Merker, Sabine & Petrova 2011). The collecting 
lymphatic vessels are analogous to the veins in the respect that lymph is propelled forward by 
the intrinsic contractility of SMCs, contractions of adjacent skeletal muscles, and arterial 
pulsations, and backflow is prevented by valves (Muthuchamy, Zawieja 2008). 
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2.3.2 Lymphangiogenesis 
The lymphatic system in the human embryo begins to develop about a month later than the first 
blood vessels, at around embryonic week 6 or 7 (Wilting, Neeff & Christ 1999). It is assumed 
that lymphatic vessels sprout from veins when a subpopulation of ECs in the cardinal vein 
starts to express PROX1, signifying their commitment to the LEC lineage (Figure 4) (Wigle, 
Oliver 1999, Kaipainen et al. 1995). Prox1 is a lymphatic hallmark gene and its expression is 
induced by Sox18 and COUP-TFII (the orphan nuclear receptor chicken ovalbumin upstream 
promoter transcription factor 2), as evidenced by experiments performed in mice (Srinivasan et 
al. 2010, Francois et al. 2008). COUP-TFII further interacts with PROX1 by forming a protein 
complex, which is known to control the expression of several LEC genes, including VEGFR3 
(Lin et al. 2010, Lee et al. 2009). Notch signaling has been proposed to function as a negative 
regulator of LEC specification, as loss of Notch1 results in a surplus of LEC progenitors in 
mouse embryos (Murtomaki et al. 2013). As a consequence of PROX1 expression, LEC 
progenitors bud off from the cardinal vein while starting to express podoplanin and then 
migrate along a gradient formed by VEGF-C, concomitantly creating the first lymphatic 
structures, the lymph sacs, which further give rise to a primary lymphatic capillary plexus 
(Yang, Oliver 2014). In addition to VEGF-C, CCBE1 is required for the budding of LEC 
progenitors from the cardinal vein (Bos et al. 2011). In fact, Ccbe1 has been shown to regulate 
Vegfc-mediated induction of Vegfr3 signaling during developmental lymphangiogenesis in 
zebrafish (Le Guen et al. 2014). Several factors influencing lymph sac formation have also been 
identified lately, including components of adrenomedullin signaling, TIE1 (Tyrosine kinase 
with immunoglobulin-like and EGF-like domains 1) which is an angiopoietin receptor, and 
GATA2 (Yang, Oliver 2014). Vessels spread by sprouting throughout the embryo from the 
primary lymphatic capillary plexus (Norrmen et al. 2011). Lymphatic sprouting requires an 
interaction between NRP2 and VEGFR-3 in response to VEGF-C, and this process can be 
inhibited in vivo by preventing VEGF-C from binding to NRP2 (Xu et al. 2010). The formation of 
a hierarchical network of capillaries and collecting vessels is finalized by remodeling and 
maturation (Adams, Alitalo 2007). A small population of LEC progenitors remains inside the 
cardinal vein and forms the lymphovenous valve, which is needed to return lymph fluid back 
to systemic blood circulation (Srinivasan, Oliver 2011).  
Much of the current knowledge of the embryonic development of the lymphatic system has 
emerged from studies performed in knockout mouse models, which have revealed a number of 
the genes responsible for lymphatic development. Mice with inactivated Sox18 or COUP-TFII 
suffer a total blockade of LEC differentiation (Lin et al. 2010, Francois et al. 2008). Prox1- and 
Vegfc-deficient mice do not develop any lymphatic structures either due to failed budding and 
sprouting of LECs (Karkkainen et al. 2004, Wigle, Oliver 1999). The number of LECs is reduced 
in Prox1+/- embryos because of decreased progenitors in the cardinal vein (Srinivasan, Oliver 
2011). Interestingly, conditional deletion of Prox1 at any developmental or postnatal stage leads 
to the reversal of LEC identity to a blood endothelial cell-like fate, demonstrating that LECs 
require the continual expression of PROX1 in order to maintain their phenotypic identity 
(Johnson et al. 2008). Vegfc+/- mice are viable but suffer from a lymphatic deficiency and 
lymphedema (Karkkainen et al. 2004). Ccbe1-/- mice lack lymphatic vessels, develop edema, and 
die prenatally (Bos et al. 2011). Additionally, VEGFR-3 kinase activity is indispensable for 
lymphatic sprouting (Zhang et al. 2010). Vegfr3-/- mouse embryos die due to cardiovascular 
defects before the emergence of lymphatic vessels, which has prevented direct assessment of the 
requirement for VEGFR-3 in the migration of LEC progenitors from the early veins (Dumont et 
al. 1998). Intriguingly, Vegfc-/-; Vegfd-/- double-knockout embryos do not phenocopy the Vegfr3-/- 
embryos, perhaps evidence for some ligand-independent VEGFR-3 signaling in the early 
embryo or that yet-to-be-determined ligands of the receptor exist (Haiko et al. 2008). VEGFR-3 
and PROX1 are closely related as it was recently shown that VEGFR-3 regulates PROX1 
expression via a positive feedback loop in LECs (Srinivasan et al. 2014). Lymphatic 
development is not compromised in Vegfd-deficient mice, but exogenous VEGF-D can rescue 
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the phenotype of Vegfc-/- mice (Baldwin et al. 2005, Karkkainen et al. 2004). The separation of 
lymphatic vessels from the blood vasculature in the mouse embryo is controlled by SYK (Spleen 
tyrosine kinase) and the adaptor protein SLP76 (SH2 domain-containing leukocyte protein of 
76kDa), and a deficiency of either one leads to abnormal lymphaticovenous connections, blood-
filled lymphatic vessels and chylous ascites (Abtahian et al. 2003). Platelets are also a 
prerequisite for lymphatico-venous separation, as they block the entry of blood into the 
developing lymphatic vessels (Zheng, Aspelund & Alitalo 2014). Podoplanin, which apart from 
being an early marker of LEC differentiation, also binds to platelet CLEC-2 (C-type lectin 
domain family 2) receptor and activates downstream SYK-SLP76 signaling (Finney et al. 2012, 
Bertozzi et al. 2010).  
Several molecules have been implicated in the maturation process of the lymphatics. FOXC2 
regulates the differentiation of the lymphatic capillary from the collecting lymphatic vessel 
phenotype through an interaction with NFATc1 (Nuclear factor of activated T cells, 
cytoplasmic, calcineurin dependent 1), which is present in LECs during the maturation of 
collecting lymphatic vessels (Norrmen et al. 2009).  Foxc2-/- mice display agenesis of lymphatic 
valves in the collecting vessels as well as ectopic coverage of SMCs and BM in capillaries 
(Petrova et al. 2004). Many of the axonal guidance molecules, which play significant roles 
during blood vessel growth, also participate in lymphangiogenesis.  Ephrin-B2, a member of the 
Eph receptor tyrosine kinase family, is essential for the maturation of collecting lymphatic 
vessels and valves. (Eichmann, Makinen & Alitalo 2005, Makinen et al. 2005.) Signaling of 
another axon guidance molecule, semaphorin 3A, via an interaction of its NRP1 and plexin A1 
receptors, is required for lymphatic valve formation (Jurisic et al. 2012, Bouvree et al. 2012). 
Furthermore, mice lacking Angpt2 (angiopoietin 2) display defective lymphatic remodeling and 
agenesis of valves, which can be genetically rescued with Angpt1 (Dellinger et al. 2008, Gale et 
al. 2002). After the first few postnatal weeks, signaling via VEGFR-3 is no longer required for 
the maintenance of pre-existing vessels, and the lymphatic vessels regenerate even should there 
be sustained inhibition of VEGFR-3, indicating that other factors in addition to VEGF-C/-D are 
required for the growth and stability of lymphatic vessels during adulthood (Karpanen et al. 
2006b). Potential postnatal factors responsible for the VEGFR-3-independent pathway include 
VEGF-A, hepatocyte growth factor (HGF), and the angiopoietins, which are all known to act as 
stimulators of lymphangiogenesis (Karpanen et al. 2006b, Kajiya et al. 2005, Tammela et al. 2005, 
Hong et al. 2004, Gale et al. 2002).  
Physiological formation of new lymphatic vessels in adult tissues is infrequent, occurring 
mainly during ovarian follicle growth and wound healing by sprouting from pre-existing 
vessels (Brown, Robker & Russell 2010, Paavonen et al. 2000). Pathological lymphangiogenesis 
is associated with tumor growth and metastasis, as well as with inflammation (Karpanen, 
Alitalo 2008). It remains unclear whether lymphatic vessel growth in adults is solely due to 
sprouting, or whether it involves incorporation of circulating or BM-EPCs, capable of 
transdifferentiating into LECs (see chapter 2.2.3 “Vasculogenesis”). Their role has been claimed 
to have been demonstrated in mice models as well as in human kidney transplants, but it 
remains a topic of some controversy (Kerjaschki et al. 2006, Buttler et al. 2006, Religa et al. 2005). 
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Figure 4. Developmental lymphangiogenesis. Expression of PROX1 marks the first LECs within 
embryonic veins. VEGFR-3 signaling is focal throughout lymphangiogenic growth and is enhanced by 
NRP2. FOXC2, Ephrin-B2, NRP1 and ANG2 among other factors are involved in the regulation of the 
late stages of lymphatic differentiation. Adapted by permission from Macmillan Publishers Ltd: Nat 
Rev Mol Cell Biol., Adams & Alitalo, “Molecular regulation of angiogenesis and lymphangiogenesis” © 
2007. 
 
2.3.3 Lymphatic vessel markers 
The identification of several lymphatic vascular specific molecular markers has made possible 
the distinction between blood and lymphatic vessels and facilitated research into finding targets 
for selectively promoting or inhibiting lymphangiogenesis in pathological conditions. 
Lymphatic capillaries and the collecting vessels differ in their pattern of lymphatic endothelial 
marker expression (Norrmen et al. 2011). The earliest marker indicating lymphatic endothelial 
competence during embryonic development, as well as one of the most widely exploited 
lymphatic markers, is lymphatic vascular endothelial hyaluronan receptor-1 (LYVE-1) (Banerji 
et al. 1999). This protein is highly expressed in lymphatic capillaries but mostly absent from 
collecting lymphatics (Tammela et al. 2007, Makinen et al. 2005). Other markers expressed in 
mature lymphatic capillaries include PROX1, VEGFR-3, and the transmembrane glycoprotein, 
podoplanin (Johnson et al. 2008, Wigle, Oliver 1999, Breiteneder-Geleff et al. 1999, Kaipainen et 
al. 1995). In mature collecting vessels, expression of VEGFR-3, PROX1, and FOXC2 is 
downregulated from the high levels observed during development (Norrmen et al. 2011). One 
further distinction between lymphatic capillaries and collecting lymphatics can be made with 
SMCs: collecting lymphatics are covered by SMCs unlike lymphatic capillaries (Jurisic, Detmar 
2009). Interestingly, intraluminal collecting vessel valves display a different molecular 
expression pattern from the nearby cells of the collecting vessel trunk, with high levels of 
VEGFR-3, PROX1, and FOXC2 (Norrmen et al. 2011). Both lymphatic and blood vascular 
endothelium express the adhesion molecule CD31 (PECAM-1) (Jurisic, Detmar 2009). 
 
 
2.3.4 Lymph nodes 
Lymph nodes are discrete, bean-shaped organs composed of fibrovascular tissue and 
surrounded by a collagenous capsule (Figure 5) (Young et al. 2006). They act as filters to trap 
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infectious agents, as well as hubs for lymphocytes and antigen-presenting cells (APCs) (Kumar, 
Abbas & Fausto 2005). Humans have approximately 450 identifiable lymph nodes, which exist 
mostly in groups at circulation bottlenecks, e.g. in axillae, groins and the neck (Young et al. 
2006, Willard-Mack 2006). Lymph nodes are highly plastic and enlarge greatly when mounting 
an immunological response (Young et al. 2006). Lymph flows into the lymph node via afferent 
lymphatics that pierce the capsule, subsequently passing through the nodal medullary sinuses, 
and finally exiting through the hilum into efferent lymphatic vessels (Guyton, Hall 2006). The 
uninterrupted influx of lymph and APCs through the afferent lymphatic vessels is a 
prerequisite for the maintenance of lymph nodes, and without constant flow lymph nodes will 
atrophy and regress in size (Tammela et al. 2007, Mebius et al. 1991). Atrophy is characterized 
by lymphoid depletion, i.e. a decrease in the number of germinal centers and depletion of 
paracortical lymphocytes, and it can either be focal, multifocal or diffuse within a lymph node 
(Elmore 2006). 
Lymphocytes, the cells which are responsible for acquired immunity, are exposed to a variety 
of antigens in lymph nodes. They circulate continually between the lymphatic and blood 
vasculature, and enter the lymph nodes mainly by migrating across the walls of special 
postcapillary venules called high endothelial venules. (Young et al. 2006.) The T and B cells 
interact with APCs and undergo clonal expansion in their respective areas inside the node: B 
cells proliferate within the follicles to form distinctive germinal centers, which are subsequently 
referred to as secondary follicles, whereas T cells proliferate in the paracortex concomitantly 
enlarging it (Willard-Mack 2006). B cells mature into plasma cells that secrete antibodies and 
exit the node along with the efferent lymph in order to circulate to the site of damage (Young et 
al. 2006). Tissue macrophages line the sinusoids of lymph nodes and phagocytize any foreign 
particles that might enter the sinus by way of the lymph (Guyton, Hall 2006). Tingible body 
macrophages are a type of macrophages containing apoptotic cell debris; these cells are found 
predominantly in the germinal centers (Willard-Mack 2006). 
It was believed for over a century that lymph nodes arise from embryonic primitive lymph 
sacs, when a mesenchymal bud protrudes into the sac and begins to acquire endothelial 
coverage in tandem with its expansion (Mebius 2003). However, recent research has revealed 
that lymph node formation is at least initiated normally in mice devoid of lymph sacs, although 
the following hematopoietic cell clustering within the lymph nodes is attenuated (Vondenhoff 
et al. 2009). Nevertheless, a highly coordinated series of interactions between hematopoietic 
cells and stromal cells residing at sites of future lymphoid organs is crucial for the development 
of secondary lymphoid organs (van de Pavert, Mebius 2010). They do not all develop at the 
same time, but sequentially, with the mesenteric lymph nodes forming first and Peyer’s patches 
last (Mebius 2003). The genes regulating lymphoid organogenesis differ from those regulating 
lymphangiogenesis, for example, lymphotoxin beta receptor signaling is pivotal for lymph node 
development but not essential for lymphatic vessel development (Furtado et al. 2007, Futterer et 
al. 1998). New lymph nodes do not form after embryogenesis, although the development of so-
called isolated lymphoid follicles occurs in the small intestine of adults (Randall, Carragher & 
Rangel-Moreno 2008). Moreover, tertiary lymphoid tissues develop in adult non-lymphoid 
organs in response to chronic inflammation, infection, and autoimmunity (Carragher, Rangel-
Moreno & Randall 2008). Intriguingly, artificial lymph nodes composed of stromal and 
dendritic cells embedded in collagenous scaffolds have been shown to induce potent immune 
responses in immune-deficient mice, pointing to a novel approach for strengthening the 
immune system or replacing damaged lymph nodes (Okamoto et al. 2007). 
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Figure 5. The structure of a lymph node. Lymph from the afferent lymphatic vessels flows through 
the subcapsular, trabecular and ultimately medullary sinuses, which converge at the hilum. Lymph 
then exits the lymph node via the efferent lymphatic vessel. Valves in the lymphatic vessels prevent 
backflow. Public domain image, courtesy of Wikimedia Commons. 
 
2.4 MOLECULAR REGULATION OF BLOOD AND LYMPHATIC VESSEL 
GROWTH 
2.4.1 Hypoxia-inducible factors 
HIFs are highly-conserved transcription factors that regulate the hypoxic response in all 
metazoan species examined to date (Loenarz et al. 2011). They activate transcriptionally 100-200 
genes that are involved in erythropoiesis, angiogenesis, autophagocytosis and energy 
metabolism (Kaelin, Ratcliffe 2008). HIF-1 is a heterodimer composed of a constitutively 
expressed beta subunit, and an alpha unit that is also continually translated but subjected to 
rapid proteasomal degradation under normoxic conditions (Huang et al. 1996, Wang et al. 
1995). Degradation occurs when two proline residues of the alpha subunit are hydroxylated by 
prolyl-hydroxylases in the presence of O2, followed by the binding of the von Hippel-Lindau 
tumor suppressor protein (pVHL) and concomitant recruitment of the E3 ubiquitin-protein 
ligase, which eventually leads to ubiquitylation and degradation of HIF-1α by a proteasome 
(Figure 6) (Jaakkola et al. 2001, Kamura et al. 2000, Maxwell et al. 1999). Conversely, the rate of 
HIF hydroxylation is suppressed by hypoxia. When oxygen is not readily available, HIF-1α 
accumulates and is transported to the nucleus, where it dimerizes with HIF-1β and binds to 
hypoxia responsive element (HRE) of the target gene promoter (Semenza et al. 1996, Wang et al. 
1995). HIF-1 has many target genes, e.g. erythropoietin, VEGF-A, VEGFR-1, and PDK1 
(Pyruvate dehydrogenase kinase, isozyme 1), which is capable of reducing oxygen consumption 
of cells, maintaining ATP (adenosine triphosphate) levels under hypoxia, and attenuating 
mitochondrial reactive oxygen species production to rescue cells from hypoxia-induced 
apoptosis (Papandreou et al. 2006, Kim et al. 2006, Gerber et al. 1997, Jiang et al. 1996, Forsythe 
et al. 1996). The transcriptional activity of HIF is further regulated by the factor inhibiting HIF-1 
(FIH-1), which represses its transactivation function in normoxic and moderately hypoxic 
conditions (Mahon, Hirota & Semenza 2001). The pivotal role of HIF-1 in the development of 
the circulatory system is underlined by the fact that Hif1α-/- mice die by E10.5 due to cardiac 
malformations, vascular defects and impaired erythropoiesis (Yoon et al. 2006, Iyer et al. 1998). 
Increased HIF-1α expression contributes to tumor progression, whereas loss of HIF activity 
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results in decreased tumor growth, thus making it a potential therapeutic target (Semenza 
2010). Conversely, HIF-1 can mediate protective physiological responses in ischemic diseases by 
activating genes encoding multiple angiogenic growth factors, and it has been shown to 
promote arteriogenesis and to increase muscle perfusion in occluded rabbit hindlimbs (Patel et 
al. 2005). Due to its role as a master regulator of hypoxic angiogenesis, HIF-1 has been proposed 
to represent a better therapeutic target than a single angiogenic factor (Semenza 2012). 
Interestingly, recent findings have suggested that HIF-1α may also have a central role in the 
initiation and regulation of lymphangiogenesis in response to hypoxia, inflammation and 
lymphatic stasis (Zampell et al. 2012, Bridges et al. 2012). 
HIF-2α has a similar structure to HIF-1α but a different expression pattern, as HIF-2α is only 
expressed in certain tissues in contrast to the ubiquitously expressed HIF-1α. HIF-2α expression 
is prevalent in endothelium, as well as in well-vascularized tissues like kidney, lung, heart, and 
small intestine. (Wiesener et al. 2003, Tian, McKnight & Russell 1997, Ema et al. 1997.) Hif2α-/- 
mice die by E16.5 because of bradycardia, vascular defects, and incomplete lung maturation 
(Compernolle et al. 2002, Tian et al. 1998). The two HIF-α subunits regulate both common and 
unique target genes. HIF-2α is unable to activate HIF-1α regulated glycolytic enzymes such as 
lactate dehydrogenase, but enhances the expression of some of the same angiogenic target 
genes as HIF-1α, e.g. VEGF-A and VEGFR-1 (Takeda et al. 2004, Hu et al. 2003). HIF-2α has 
been shown to induce angiogenesis in a mouse model of wound healing (Takeda et al. 2004). 
Moreover, it has been found to promote tumorigenesis, particularly in neuroblastoma and renal 
cell carcinoma (Holmquist-Mengelbier et al. 2006, Kondo et al. 2003). HIF-3α, another HIF 
isoform, is claimed to be an inhibitory regulator of angiogenesis and hypoxic response, and it is 
highly expressed in the cornea, where there is a low level of hypoxia-inducible VEGF-A 
expression and an avascular phenotype (Makino et al. 2001). 
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Figure 6. HIF signaling under normoxic and hypoxic conditions. Under normal oxygen supply, proline 
residues of HIF-1α are hydroxylated by prolyl hydroxylase, followed by the binding of the Von 
Hippel-Lindau protein (pVHL), which is a component of a ubiquitin ligase complex. This leads to HIF-
1α ubiquitination and proteasomal degradation. When there is a poor oxygen supply, hydroxylation 
is inhibited leading to accumulation of HIF-1α, which is transported to the nucleus where it dimerizes 
with HIF-1β and then binds to the hypoxia-response element (HRE) of target genes, activating their 
transcription. © 2013 Paula Province, Corinne E. Griguer, Xiaosi Han, Nabors Louis B. and Hassan 
Fathallah Shaykh. Adapted from “Evolution of the Molecular Biology of Brain Tumors and the 
Therapeutic Implications”, originally published under CC BY 3.0 license. Available from: 
http://dx.doi.org/10.5772/53298  
 
2.4.2 Vascular endothelial growth factors and their receptors 
VEGFs are secreted glycoproteins with several isoforms generated by alternative splicing and 
post-translational processing (Jeltsch et al. 2013). They are the main regulators of blood and 
lymphatic vessel formation during embryological development as well as in physiological and 
pathological conditions in adults. The VEGF family comprises VEGF-A, placental growth factor 
(PlGF), VEGF-B, VEGF-C and VEGF-D. (Lohela et al. 2009.) In addition to these five members 
found in mammals, viral VEGF homologues (VEGF-E) produced by Orf viruses and snake 
venom VEGF (VEGF-F) have been identified (Yamazaki, Morita 2006, Ogawa et al. 1998). 
VEGFs bind to cellular receptor tyrosine kinases VEGFR-1, VEGFR-2 and VEGFR-3 as well as to 
co-receptors NRP1 and NRP2 with varying affinities and selectivities (Lohela et al. 2009). 
Additionally, there is a heparin binding domain in VEGF that interacts with heparan sulfate 
proteoglycans (HSPG), which are also able to serve as co-receptors (Koch et al. 2011). The 
VEGFs and their binding to VEGF and NRP receptors are illustrated in Figure 7. 
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Figure 7. VEGFs and their receptors. VEGF-A binds to both VEGFR-1 and VEGFR-2, whereas VEGF-B 
and PlGF bind to only VEGFR-1. VEGF-C and -D bind to both VEGFR-3 and VEGFR-2. NRP1 and NRP2 
act as co-receptors and modulate VEGFR activation and signaling.  All VEGFs bind to both NRP1 and 
NRP2, except for VEGF-B, which binds to only NRP1. Different VEGF-A isoforms have different 
binding properties towards the NRP receptors. Adapted by permission from The American 
Physiological Society: Physiol Rev., de Almodovar et al., “Role and Therapeutic Potential of VEGF in 
the Nervous System” © 2009. 
 
2.4.2.1 VEGF-A 
VEGF-A binds to VEGFR-1 and -2 and is upregulated under hypoxic conditions (Ferrara, 
Gerber & LeCouter 2003, Minchenko et al. 1994). It is produced in at least eight different 
isoforms due to alternative splicing of mRNA from a single VEGFA gene (Dehghanian, Hojati & 
Kay 2014). VEGF-A165 is the most abundant and biologically active isoform that binds to 
VEGFR-1, VEGFR-2, NRP1 and NRP2. In addition, VEGF-A165 is able to bind HSPGs. Different 
VEGF-A isoforms vary in their affinities towards NRP and HSPG co-receptors. (Koch et al. 
2011.) VEGF-A has a dominant role in embryonic vasculogenesis and angiogenesis, as Vegfa+/- 
embryos die between E11 and E12 due to defects in blood vessel formation (Carmeliet et al. 
1996). In addition, VEGF-A has been shown to increase vascular permeability, to promote EC 
proliferation and migration, to inhibit apoptosis, and to induce vasodilation indirectly via NO 
release. Excessive levels of VEGF-A contribute to several pathological conditions, such as tumor 
angiogenesis, diabetic retinopathy and polycystic ovary syndrome. (Ferrara, Gerber & LeCouter 
2003.) Consequently, VEGF-A has become the primary drug target for antiangiogenic therapy 
with several VEGF-A–based inhibitors approved for clinical use by the U.S. Food and Drug 
Administration (FDA) (Crawford, Ferrara 2009). However, only a fraction of patients appear to 
benefit from the therapeutic blockade of angiogenesis, as tumors are capable of developing 
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resistance mechanisms to VEGF-A inhibitors (Bergers, Hanahan 2008). In addition to being the 
key regulator of angiogenesis, VEGF-A has been shown to induce the growth of lymphatic 
vessels, which although abnormal in shape and functionality, become VEGF-A independent 
once formed and persist indefinitely (Nagy et al. 2002). However, the lymphangiogenic effects 
of VEGF-A have been attributed to the recruitment of VEGFR-1 expressing inflammatory cells 
that secrete lymphangiogenic factors (Cursiefen et al. 2004). The weak lymphangiogenic 
potential of VEGF-A is supported by the observation that deletion of Vegfr2 from lymphatic 
vessels results in hypoplastic but functional lymphatic vessels in embryos and adult mice 
(Dellinger et al. 2013). 
 
2.4.2.2 VEGF-B 
VEGF-B is a ligand for VEGFR-1 and NRP1, and unlike VEGF-A, it is not regulated by hypoxia 
(Makinen et al. 1999, Enholm et al. 1997). It is produced in two isoforms: freely soluble VEGF-
B186 and heparin-binding VEGF-B167 (Olofsson et al. 1996b). VEGF-B is abundantly expressed in 
tissues with active energy metabolism needs, such as myocardium, striated muscle and brown 
fat, indicating a role in supporting metabolic functions. In many tissues, VEGF-B is coexpressed 
with VEGF-A, and the two can also join to form heterodimers which then bind to VEGFR-2. 
(Bry et al. 2014, Olofsson et al. 1996a.) Although the ability of VEGF-B to induce angiogenesis in 
most tissues is weak, it has been shown to be a promising candidate for both therapeutical 
angiogenesis in myocardium as well as in the prevention of heart failure (Huusko et al. 2012, 
Lahteenvuo et al. 2009). Vegfb-/- mice have been reported to have small hearts and impaired 
recovery from ischemia, but they are viable and fertile in contrast to Vegfa knockout mice. Thus, 
VEGF-B is not essential for the development of the cardiovascular system. (Aase et al. 2001, 
Bellomo et al. 2000.) 
 
2.4.2.3 VEGF-C 
VEGF-C is a primarily lymphangiogenic factor that binds to VEGFR-3 and NRP2 with high 
affinity in its full length, unprocessed form, and with increasing affinity to VEGFR-2 in its 
proteolytically processed form (Xu et al. 2010, Joukov et al. 1997). The full length form is mainly 
lymphangiogenic, which is in agreement with its strong binding to VEGFR-3, whereas the 
mature short form promotes angiogenesis and vascular permeability via VEGFR-2 (Veikkola et 
al. 2001, Cao et al. 1998, Joukov et al. 1997). CCBE1 has been shown recently to enhance the 
proteolytic cleavage of inactive VEGF-C into a potent form, which is able to activate its cognate 
receptor VEGFR-3 (Jeltsch et al. 2014). During embryogenesis, VEGF-C is highly expressed in 
regions of lymphatic vessel development (Kukk et al. 1996). In Vegfc-/- mice, ECs cannot sprout 
to form lymphatic vessels, whereas Vegfc+/- mice display lymphatic hypoplasia and lymphedema 
(Karkkainen et al. 2004). The expression of VEGF-C decreases in most fully developed tissues 
but remains high in lymph nodes (Saaristo et al. 2012, Lymboussaki et al. 1999). Over-
expression of VEGF-C has proven effective in the induction of lymphatic vessel growth in 
several animal models (Tammela et al. 2007, Saaristo et al. 2002a, Enholm et al. 2001). Although 
VEGF-C does not appear to increase the growth of primary tumors, it has been shown to 
promote lymphatic metastasis of tumor cells (Hirakawa et al. 2007, Skobe et al. 2001). The 
expression of VEGF-C and VEGF-D directly correlates with lymphatic invasion, lymph node 
involvement, distant metastasis, and sometimes poor prognosis of survival (Achen, Stacker 
2008). An engineered isoform of VEGF-C, VEGF-C156S, has been shown to be a selective 
agonist of VEGFR-3 and capable of inducing lymphangiogenesis but it does not exert any 
effects on the blood vasculature (Rissanen et al. 2003b, Saaristo et al. 2002b, Joukov et al. 1998). 
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2.4.2.4 VEGF-D 
VEGF-D, like VEGF-C, is considered to be a lymphangiogenic factor, although it is not essential 
for the formation of the lymphatic system and its physiological role remains unclear. Vegfd-/- 
mice are healthy and do not diplay any obvious abnormalities in their phenotype. (Baldwin et 
al. 2005.) Endogenous VEGF-D is not able to compensate for the lack of VEGF-C in embryonic 
lymphatic development, although in Vegfc-/- mice, exogenous VEGF-D can rescue sprouting of 
ECs committed to the lymphatic lineage, at least to some extent (Karkkainen et al. 2004). The 
expression of VEGF-D in the adult is strongest in the heart, lung, skeletal muscle, and the 
intestine (Achen et al. 1998). The binding affinity of VEGF-D to its receptors is very similar to 
that of VEGF-C, with the full-length form binding primarily to VEGFR-3 and NRP2, and the 
mature, proteolytically processed form (VEGF-DΔNΔC) preferring VEGFR-2 (McColl et al. 2007, 
Achen et al. 1998). The fully processed form of VEGF-D has a 290-fold greater affinity towards 
VEGFR-2 than the full-length VEGF-D (Stacker et al. 1999). Proteolytic prosessing is required 
for the angiogenic activity of VEGF-D, and in concordance with this, VEGF-DΔNΔC has been 
found to induce strong angiogenesis in rabbit hind limb skeletal muscle (Rissanen et al. 2003b). 
Over-expression of full-length VEGF-D and VEGF-DΔNΔC alike has been shown to induce 
lymphatic vessel growth in mice (Tammela et al. 2007, Veikkola et al. 2001). Importantly, with 
regard to safety considerations, VEGF-D has been implicated in tumor metastasis and 
spontaneous tumor formation (Karkkainen et al. 2009, Ishii et al. 2004). 
 
2.4.2.5 PlGF 
PlGF is expressed in placenta, thyroid and lungs in the adult, and binds VEGFR-1 as well as 
NRP1 and NRP2 (Fischer et al. 2008, Ziche et al. 1997, Clauss et al. 1996). PlGF has four different 
isoforms in humans, of which PlGF-1 and -3 are freely soluble and -2 and -4 bind to heparin 
(Yang et al. 2003, Cao et al. 1997). The deletion of PlGF does not cause any overt vascular 
defects or infertility in mice. Although PlGF is redundant for angiogenesis during development, 
it appears to be angiogenic in pathological settings, as Plgf-/- mice exhibit impaired angiogenesis 
and arteriogenesis during ischemia, inflammation, wound healing and tumor growth. 
(Carmeliet et al. 2001.) Over-expression of PlGF has been shown to induce revascularization of 
ischemic limb and myocardium and enhanced healing of wounds in diabetic mice (Cianfarani et 
al. 2006, Luttun et al. 2002). Its angiogenic properties are at least in part explained by its ability 
to enhance VEGF-A signaling. Firstly, PlGF can displace VEGF-A from VEGFR-1, thus allowing 
VEGF-A to bind VEGFR-2, resulting in angiogenic signaling (Fischer et al. 2008). Secondly, PlGF 
can upregulate the expression of VEGF-A and other angiogenic growth factors (Roy et al. 2005). 
Furthermore, an intermolecular crosstalk between VEGFR-1 and -2 occurs when VEGFR-1 is 
activated by PlGF, which consequently promotes VEGF-A mediated angiogenesis (Autiero et al. 
2003). PlGF is also able to signal through VEGFR-1 independently of VEGF-A (Fischer et al. 
2008). However, there are a few studies indicating that PlGF might be a weak EC mitogen in 
vitro and capable of inducing only a weak signal via VEGFR-1 (Migdal et al. 1998, Park et al. 
1994). 
 
2.4.2.6 VEGF-receptors 
VEGFs bind to their cognate tyrosine kinase receptors, VEGFRs, on the cell surface, causing 
them to dimerize and become activated through transphosphorylation, which then leads to 
coordination of the cellular responses regulated by downstream signaling molecules. VEGFRs 
comprise an extracellular, ligand-binding domain consisting of seven immunoglobulin-like 
domains, a transmembrane domain, a juxtamembrane domain, an intracellular split tyrosine 
kinase domain, and a C-terminal tail. (Koch et al. 2011.) Receptor activity is largely controlled 
by trafficking mechanisms, e.g. regulating the numbers of receptors at the cell surface, the rate 
at which these receptors are internalized, and the degradation vs. recycling of receptors (Zhang, 
Simons 2014).  
29 
 
 
VEGFR-1 is necessary for the development of the embryonic vasculature, as Vegfr1-/- mice 
form abnormal vascular structures and die in utero. The disorganization of vasculature was 
found to be a consequence of excess EC progenitors, evidence of an inhibitory role for VEGFR-1 
in the regulation of angiogenesis. (Fong et al. 1999, Fong et al. 1995.) VEGFR-1 displays a high 
afiinity towards VEGF-A, VEGF-B and PlGF, the latter two of which share structural similarities 
(Tammela et al. 2005). VEGFR-1 also has a naturally occurring soluble form (sVEGFR-1) 
comprising the extracellular part of VEGFR-1; this is thought to act as a VEGF-A trap, further 
implying an inhibitory role for this receptor in VEGF-A induced angiogenesis (Hiratsuka et al. 
1998, Kendall, Thomas 1993). In contrast, VEGFR-1 is capable of promoting proangiogenic 
signals by binding PlGF and thereby indirectly activating VEGFR-2 (Autiero et al. 2003). The 
expression of VEGFR-1 is directly upregulated by hypoxia via a HIF binding enhancer element 
in the VEGFR-1 promoter, and it is expressed not only in ECs but also in macrophages, 
pericytes, renal mesangial cells, placental trophoblasts and many other cell types (Tammela et 
al. 2005, Gerber et al. 1997). VEGFR-1 is able to transmit only weak mitogenic signals in ECs by 
itself. However, it can form heterodimers with VEGFR-2 that possess a stronger signaling 
capacity. (Huang et al. 2001.) VEGFR-1 has also been shown to engage in macrophage 
recruitment to promote tissue remodeling (Pipp et al. 2003). 
VEGFR-2 is the main mediator of EC differentiation, proliferation and migration, as well as 
vascular tube formation and vascular permeability (Koch et al. 2011, Gille et al. 2001). Ligand 
binding to VEGFR-2 leads to a robust angiogenic response. VEGFR-2 binds VEGF-A, the mature 
forms of VEGF-C and VEGF-D, VEGF-E, and also VEGF-F. (Koch et al. 2011, Yamazaki et al. 
2003.) It is highly expressed in the vascular endothelium during embryogenesis (Quinn et al. 
1993). VEGFR-2 is pivotal for the development of the vascular system, as Vegfr2-/- mice die 
between E8.5-9.5 after failing to develop endothelial and hematopoietic cells (Shalaby et al. 
1995). Recent research has pointed to a role for VEGFR-2 in lymphatic vessel sprouting as well 
(Dellinger et al. 2013). After birth, VEGFR-2 expression decreases but is upregulated again in 
times of physiological and pathological angiogenesis in the adult (Jeltsch et al. 2013). VEGFR-2, 
like VEGFR-1, has a soluble form, which acts as a VEGF-C trap, preventing VEGF-C from 
binding to VEGFR-3 and consequently inhibiting its lymphangiogenic effects (Albuquerque et 
al. 2009). 
VEGFR-3 has an important role in the formation of the lymphatic system and it is activated 
by both the full-length and the processed forms of VEGF-C and VEGF-D (Jeltsch et al. 2013). 
VEGF-C binding to VEGFR-3 triggers signals to promote proliferation, migration and survival 
of LECs (Salameh et al. 2005, Makinen et al. 2001). VEGFR-3 activation can also occur 
independently of ligand-binding and in response to mechanical signals. An elevation in the 
interstitial pressure in mice embryos was found to be sufficient to phosphorylate VEGFR-3, 
thereby promoting LEC proliferation and lymphatic vessel growth. (Planas-Paz et al. 2012.) The 
key role of VEGFR-3 in lymphatic function is highlighted by the fact that missense mutations in 
this receptor lead to hereditary lymphedema in humans and a similar condition in mice 
(Karkkainen et al. 2001, Karkkainen et al. 2000, Irrthum et al. 2000). VEGFR-3 is expressed in all 
endothelia at the beginning of development but it becomes restricted to LECs, with the 
exception of some fenestrated capillaries e.g. those found in endocrine organs, as the lymphatic 
system starts to develop (Partanen et al. 2000, Kaipainen et al. 1995). In addition to being 
expressed in normal lymphatics, VEGFR-3 appears as a positive marker in some pathological 
conditions such as vascular tumors and neovascularization of nonvascular tumors (Partanen, 
Alitalo & Miettinen 1999). VEGFR-3 is known to play a crucial role in the formation of the 
vascular system already before the appearance of lymphatics, as indicated by the finding that 
Vegfr3-/- mice die in utero due to the defective formation of vasculature and cardiovascular 
failure (Dumont et al. 1998). VEGFR-3 is able to heterodimerize with VEGFR-2, and these 
heterodimers appear to be active in sprouting angiogenesis (Nilsson et al. 2010). Moreover, 
antibodies against VEGFR-3, which inhibit both VEGFR-3 homodimerization and VEGFR-
2/VEGFR-3 heterodimerization, lead to decreased vascular and lymphatic EC migration and 
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vessel sprouting (Tvorogov et al. 2010). Similarly as in the case of VEGFR-2, the soluble form of 
VEGFR-3 appears to limit the local activity of VEGFR-3 and subsequent lymphangiogenesis in 
some tissues, such as the cornea (Singh et al. 2013). 
 
2.4.2.7 NRP-receptors 
NRP1 and NRP2 are receptors for class 3 semaphorins, which mediate inhibitory signals during 
neuronal axon guidance (Koch et al. 2011). They also engage in angiogenesis and VEGFR 
signaling where they act as co-receptors, with NRP1 binding VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, PlGF and VEGF-E, and NRP2 binding VEGF-A, VEGF-C, VEGF-D and PlGF 
(Uniewicz, Fernig 2008, Karpanen et al. 2006a, Makinen et al. 1999, Soker et al. 1998). NRPs have 
been postulated to play a role in determining the arterial or venous fate of blood vessels, since 
in the course of embryonic development, NRP1 expression is mostly prevalent in arteries and 
NRP2 primarily marks veins (Herzog et al. 2001). 
NRP1 contributes to EC migration and survival owing to its effects on VEGF-A-VEGFR-2 
interactions (Koch et al. 2011). Additionally, it has been linked to VEGFR-2 mediated vascular 
permeability and VEGF-A induced sprouting and branching of ECs (Kawamura et al. 2008, 
Becker et al. 2005). The deletion of the Nrp1 gene is lethal, causing a wide range of vascular and 
neuronal defects in mouse embryos, whereas over-expression of NRP1 leads to embryonic 
lethality in mice due to excessive formation of vessels, hemorrhages and cardiac malformations 
(Gu et al. 2003, Kawasaki et al. 1999, Kitsukawa et al. 1995). The blockade of NRP1 function 
with a specific antibody has reduced angiogenesis and vascular remodeling in vivo and 
rendered vessels more susceptible to anti-VEGF-A therapy in the battle against tumor growth 
(Pan et al. 2007). 
NRP2 is expressed not only in veins but also in lymphatic vessels and it can interact with 
VEGFR-2 and VEGFR-3 to promote the migration and the survival of ECs (Koch et al. 2011, 
Favier et al. 2006). Nrp2-/- mice are characterized by the absence of small lymphatic vessels and 
capillaries at birth, with blood vessels and larger collecting lymphatics developing normally. 
No signs of edema were observed in the nullizygous Nrp2 mice despite a reduced number of 
lymphatic vessels in the skin and the internal organs. Lymphatic vessel growth occurred 
postnatally in these mice, albeit abnormally patterned, particularly in the heart and the 
intestine. (Yuan et al. 2002.) The mechanism by which NRP2 could modulate 
lymphangiogenesis was later shown to be through an interaction with VEGFR-3 to mediate 
VEGF-C-induced lymphatic sprouting (Xu et al. 2010). Administration of an anti-NRP2 
antibody was able to reduce the metastatic spread of tumor cells, tumoral lymphangiogenesis 
and functional lymphatics in tumors without affecting established lymphatics in mice (Caunt et 
al. 2008). 
 
2.5 GENE THERAPY  
A gene, consisting of a sequence of DNA, is the fundamental unit of heredity that determines a 
particular characteristic in an organism (Nelson, Cox 2008). Gene therapy is a form of molecular 
medicine that utilizes genes in treating or preventing diseases. One can take different 
approaches to gene therapy, e.g. replacing a mutated disease-causing gene with a healthy copy 
of the gene, inactivating a mutated gene that is functioning undesirably, or introducing a new 
gene into target cells to help fight disease. (Wally, Murauer & Bauer 2012, Drude et al. 2007, Yla-
Herttuala, Alitalo 2003.) The possibility of using endogenous proteins to locally treat only the 
affected tissues as well as the potential long-term therapeutic effect achieved by a single 
application are considered as advantages of gene therapy over conventional therapeutic 
modalities (Yla-Herttuala, Alitalo 2003). 
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For gene therapy to achieve its goals, a sufficient amount of the therapeutic gene and/or its 
product should be delivered to the target cells without causing significant toxicity. The effect 
profile of gene transfer (GT) is determined by the chosen therapeutic gene, the vector carrying 
the gene, as well as the route of administration of the GT. Different diseases present different 
requirements for gene therapy in terms of the locality of the treatment and the duration of the 
gene expression. For example, in the case of some genetic disorders, long-term expression in a 
small proportion of cells might be sufficient, whereas inhibition of cancer growth would require 
gene transfer of tumor suppressor genes to a large number of abnormal cells. (Kay, Glorioso & 
Naldini 2001.)  
Carriers called vectors are engineered to deliver the therapeutic gene into target cells. At 
present, three types of gene delivery methods are available: viral vector based, non-viral vector 
based, and physical methods. Certain genetically modified viruses are able to deliver the 
desired gene by infecting the target cell, and viral vectors in general have the advantage of high 
delivery efficiency to a variety of cells. In contrast, non-viral vectors, such as naked DNA 
plasmids, are less toxic and immunogenic than viral vectors but exhibit lower delivery 
efficiencies. Physical methods make use of a physical force to overcome the membrane barrier 
of the cell, thereby enabling intracellular GT. There are different types of physical methods e.g. 
gene delivery by needle injection and sonoporation, which utilizes ultrasound to permeabilize 
the cell membrane. For the time being, both non-viral and physical methods of gene delivery 
are generally considered unacceptable for clinical use due to their significantly lower delivery 
efficacy in comparison to viral vectors. (Kamimura et al. 2011, Verma, Weitzman 2005.) 
The duration of transgene expression in the target cell depends on the vector. Some vectors 
e.g. retroviral vectors, have the ability to integrate into the genome of the host cell leading to 
long-term gene expression that can be passed onto daughter cells. In contrast, transient 
expression of only 2-4 weeks can be achieved by the use of adenoviruses. (Kamimura et al. 
2011.) 
Vectors carrying the therapeutic gene can be delivered to the desired tissue by a range of 
different delivery routes. In the case of therapeutic angiogenesis, commonly used routes of 
delivery include local, intramuscular injections and systemic, intravascular delivery. 
Intravenous (i.v.) delivery is straightforward to execute in small animal models, but becomes 
impractical when applied to larger animals and humans due to their great blood and tissue 
volumes. (Karvinen, Yla-Herttuala 2010.) Furthermore, following the systemic spreading of the 
gene drug via i.v. administration, viral particles may tend to accumulate in unwanted 
destinations, mainly the liver, rather than in the target area (Lozier et al. 2002, Alemany, Suzuki 
& Curiel 2000). Local injections into the heart or skeletal muscles have proven to be most 
effective in achieving high expression of transgenes, and they also appear to be well tolerated 
(Karvinen, Yla-Herttuala 2010, Harvey et al. 2002). 
 
2.5.1 Viral vectors 
Viruses have an inherent ability to hijack the machinery of a host cell in order to produce 
copious amounts of their own genome. This characteristic is exploited in gene therapy, where 
viral vectors are employed to deliver therapeutic genetic material into target cells. Viral vectors 
are derived from either RNA or DNA viruses and designated as either integrating or non-
integrating vectors. In the first phase of engineering a viral vector, the viral sequences required 
for replication, the assembly of viral particles, the packaging of the viral genome, and the 
delivery of the transgene, are identified. Next, inessential genes are deleted to make room for 
the transgene and to prevent replication, as well as to reduce pathogenity and the expression of 
immunogenic viral antigens. Subsequently, the transgene cassette is inserted into the vector 
construct, which is then introduced into a packaging cell line. In a packaging cell, a separate 
packaging construct or a helper virus supplies the proteins needed for replication and assembly 
of the virion. Finally, the recombinant viral vector is produced following the encapsidation of 
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the replicated vector genomes into virus particles. (Vannucci et al. 2013, Verma, Weitzman 
2005.) 
Transduction denotes the delivery of genetic material into a precise cell via a viral vector. In 
this process, the viral vector itself does not replicate but merely carries the inserted genetic 
information to its destination. Retroviral and lentiviral vectors are able to integrate into the host 
genome holding the promise of lifelong expression, whereas DNA-based viral vectors are 
normally present as episomes in the host cell nucleus. (Vannucci et al. 2013, Kamimura et al. 
2011.) An ideal vector would be one that could be produced in high titres, would be capable of 
targeting the appropriate cell type in each case, and would lead to a stable, sustained gene 
expression without eliciting adverse effects such as undesirable immune responses. No such 
vector exists as yet, but several approaches have been adopted to overcome obstacles related to 
production, targeting the desired tissues, efficient gene delivery and pathogenity. (Verma, 
Weitzman 2005.) 
 
2.5.1.1 Adenoviral vectors 
Adenovirus was originally isolated from human adenoids in 1953 (Rowe et al. 1953). Its genome 
consists of a double-stranded linear DNA, and it is on average 36 kbp (kilobase pairs) in size 
(Davison, Benko & Harrach 2003). Usually the adenovirus infection in humans is mild but may 
pose life-threatening risks to immunocompromized individuals (Hendrickx et al. 2014). There 
are more than 100 Ad serotypes, including 51 identified human Ad serotypes; these are 
unevenly prevalent and commonly infect the lung epithelium and the gastrointestinal tract but 
also other organs (Sharma et al. 2009a). Several cell surface molecules are involved in the entry 
of the adenovirus into the cell, the most common being the Coxsackie-adenovirus receptor 
(CAR) for the majority of serotypes (Sharma et al. 2009a, Bergelson et al. 1997). 
Adenoviral vectors are mostly derived from the Ad5 serotype and to a lesser extent from 
serotype 2 (Verma, Weitzman 2005). They can be produced in high titres, they display tropism 
towards a variety of cell types, and they express the transgene at high levels, all of which make 
the adenovirus an attractive candidate for gene therapy. However, there is extensive pre-
existing immunity against the adenovirus in the population, and furthermore the adenoviral 
proteins are highly immunogenic in humans, which impact on the use of common serotypes 
and limit the number of administrations which can be given to the same individual. (Vannucci 
et al. 2013.) The expression of the transgene is transient and peaks in 1-7 days, waning to an 
undetectable level by 2-4 weeks due to both innate and acquired immune responses against 
viral proteins (Yang et al. 1996, Yang et al. 1994). The advantages and disadvantages of 
adenoviral vectors are listed in Table 2. 
Circumventing the antiadenovirus immunity has been a topic of intensive research. So-called 
“gutless” adenovirus vectors have been developed, where all the adenovirus genes are removed 
and the essential genes needed to create the vector are provided by the producer cells 
(Kamimura et al. 2011). Another approach is the concept of “seroswitch”, denoting the use of a 
different serotype adenovirus vector for the second administration, which provides another 1-2 
weeks of expression (Mastrangeli et al. 1996). The short-term expression elicited by the 
immunogenicity of the adenovirus can also be exploited to advantage. Transient expression is 
suitable for applications aimed at building new biologic structures, such as that of VEGF gene 
transfer for the generation of neovasculature (Crystal 2014). The anti-adenovirus immunity 
limits the expression of the growth factor to a few weeks, but this can be sufficient for initiating 
angiogenesis (Mack et al. 1998). Moreover, the short-term expression of the transgene caters for 
the needs of cancer gene therapy, where the goal is to destroy tumoral cells (Vannucci et al. 
2013). The strong immune response elicited by Ad can help augment the otherwise diminished 
immunity against tumor cells, further asserting its position as the most widely used oncolytic 
vector. Nevertheless, the lack of specific targeting due to widespread distribution of CAR and 
poor transduction of many tumor types because of low levels of CAR expression has warranted 
the development of several retargeting approaches. (Sharma et al. 2009b.) An example of this 
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retargeting is the use of hybrid Ad vectors, which are directed to other target-specific cellular 
receptors and have shown efficient transduction of CAR-deficient cells, reduced liver tropism 
and improved transduction of cancer cells in many different cancer types (Zheng et al. 2007, 
Suominen et al. 2006, Breidenbach et al. 2004, Kanerva et al. 2002). The potent anti-adenoviral 
immunity has also been harnessed to create vaccines against several pathogens and tumors 
(Krause, Worgall 2011). In summary, adenovirus vectors are the number one choice for high-
level, short-term expression or for deliberately evoking immunity. 
 
Table 2. Advantages and disadvantages of adenovirus vectors. Adapted by permission from 
Macmillan Publishers Ltd: Mol Ther., Rissanen & Ylä-Herttuala, “Current Status of Cardiovascular 
Gene Therapy”, © 2007. 
 
Advantages Disadvantages 
High transduction efficiency Strongly immunogenic 
Transduce both dividing and non-dividing cells Prevalence of pre-existing anti-Ad immunity in the population 
High capacity to accomodate foreign DNA (~8 
kbp) 
Predominant hepatotropism following systemic 
administration 
Well suited as oncolytic vector Transient expression (~14 days) 
Easy to produce in high titers 
 
2.5.1.2 Other viral vectors 
Adeno-associated viruses (AAV) are small DNA viruses that belong to the Parvoviridae family. 
The wild type AAV requires co-infection with adenovirus or herpesvirus in order to replicate. 
In the absence of a helper virus, wild type AAV is able to integrate into chromosome 19, where 
it remains latent until rescued by a helper virus. However, current AAV vectors do not possess 
this property. The advantages of AAV vectors include their low immunogenicity, their potential 
for site-specific integration, their wide tropism, their long expression time, and their ability to 
transduce both dividing and quiescent cells. The two main handicaps of using AAVs as vectors 
are their limited cloning capacity that is unsuited for most therapeutic genes, and the difficulty 
to achieve high vector titers. Most gene therapy trials employing AAV as gene transfer vector 
are aimed at treating monogenic diseases. (Vannucci et al. 2013, Daya, Berns 2008.) 
Lentiviruses and retroviruses are RNA viruses capable of integrating into the genome of the 
host cell, thus inducing stable transgene expression. Following entry into the target cell, the 
reverse transcriptase converts the genomic RNA into double-stranded DNA, which is then 
integrated into the host chromosome. Lentiviruses are capable of transducing both non-
dividing and dividing cells, whereas retroviruses transduce only replicating cells. (Vannucci et 
al. 2013.) Lentiviral vectors have been successfully used to treat β-thalassemia as well as 
progressive cerebral demyelination in X-linked adrenoleukodystrophy patients in clinical trials 
(Cartier et al. 2009, Kaiser 2009). Retroviral vectors have been applied in the treatment of severe 
combined immunodeficiency (SCID), which hampers T cell development and function, utilizing 
ex vivo gene transfer into autologous hematopoietic stem cells. Unfortunately, the use of first-
generation retroviral vectors was associated with the occurrence of acute leukemia in clinical 
trials, which will be further discussed in chapter 2.5.3 “Safety issues in gene therapy”. (Touzot 
et al. 2014.) 
Other more uncommon viral vectors include poxviruses, also known as Vaccinia viruses, 
which have been mostly used for the production of recombinant proteins, oncolytic cancer 
therapy, and vaccination; baculoviruses which are convenient tools for recombinant protein 
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production in insect cells but they can also transduce a plethora of mammalian cell types; and 
Sindbis virus, which is an alphavirus capable of reaching metastatic tumors when systemically 
administered due to its natural tropism for tumor cells (Vannucci et al. 2013, Airenne et al. 2013, 
Quetglas et al. 2010). 
 
2.5.2 Non-viral vectors 
Non-viral gene delivery methods can be categorized into natural vectors, such as plasmid DNA 
or small interfering RNAs (siRNAs), and synthetic carriers, such as liposomes or cationic 
polymers. Another classification categorizes non-viral vectors into either organic or inorganic 
delivery systems. (Dizaj, Jafari & Khosroushahi 2014.)  The simplest non-viral delivery method 
is the naked DNA plasmid injection (Kamimura et al. 2011). DNA-based transposon vectors, 
such as the leading non-viral vector of gene therapy called Sleeping Beauty, are based on 
integration of transposon DNA, which contains a transgene, into chromosomal DNA by a 
transposase enzyme (Aronovich, McIvor & Hackett 2011). The advantages of non-viral methods 
over viral vectors include simple large scale production, lower immunogenicity, lack of pre-
existing immunity in patients, and unlimited therapeutic gene packaging capacity. The main 
limitation of non-viral vectors is their lower gene transfer efficiency in relation to viral vectors. 
(Yin et al. 2014.) That is why at present, the vast majority of gene therapy clinical trials have 
been conducted using viral vectors (http://www.abedia.com/wiley/vectors.php). Recently, a 
plasmid DNA encoding a major histocompatibility complex class I heavy and light chains of 
HLA-B7 and β2-microglobulin complexed with a lipid-based delivery system failed to reach its 
efficacy points in a Phase III clinical trial for the treatment of advanced metastatic melanoma 
(Hersey, Gallagher 2014). Some minor setbacks regarding the safety of non-viral vectors have 
arisen over the years, as plasmid DNA was found to cause prominent inflammation in skeletal 
muscle and humans receiving intracoronary plasmid liposomes suffered a transient fever. 
(Hedman et al. 2003, McMahon et al. 1998). However, no major adverse effects have been 
reported and non-viral vectors in general are considered to have a fairly unblemished safety 
profile. 
 
2.5.3 Safety issues in gene therapy 
Worldwide, adenoviral vectors are the most commonly used vectors in gene therapy clinical 
trials, being utilized in 22.5% of all gene therapy trials 
(http://www.abedia.com/wiley/vectors.php). Consequently, extensive safety data from 
adenovirus vectors in several different clinical applications have accumulated, and a uniformly 
good safety profile has been outlined, suggesting that adenoviral gene therapy, when 
administered with relevant doses and the optimal route of administration, is safe and well 
tolerated (Muona et al. 2012, Hedman et al. 2009, Harvey et al. 2002, Crystal et al. 2002). 
Notwithstanding the generally good safety profile, adenoviral gene therapy resulted in the 
death of a young patient with ornithine transcarbamylase deficiency in 1999. The patient 
suffered multiple organ failure four days after intraportal delivery of a high-dose adenovirus 
vector, and a severe anti-Ad immune response was later determined as the cause of death. 
(Raper et al. 2003.) This tragic incident warranted efforts to circumvent the anti-Ad immunity 
with various approaches, such as progressive deletion of the genes causing inflammation and 
stimulation of the host immune response (Vannucci et al. 2013). Another death of a gene-
therapy recipient occurred in an AAV trial for the treatment of rheumatoid arthritis in 2007, 
when a 36-year-old woman died 3 weeks after she had received a second intra-articular 
injection of the AAV-vector. However, her death was considered not to have been caused by 
AAV but by an infection made possible due to the strong immunosuppressive medication. 
(Williams 2007.) 
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Another major safety issue in viral vector gene therapy concerns the disruption of important 
genes in target cells. With integrating viruses, there is a risk of insertional mutagenesis which 
means that a mutation has been created by the insertion of new genetic material into a normal 
gene. Integration of the retrovirus into the host genome may have different outcomes, the most 
probable being integration outside a cellular coding sequence or inside an irrelevant gene. 
However, in worse case scenarios, integration may lead to the death of transduced cells if it 
disrupts a vital gene, or neoplastic proliferation if the integration activates a proto-oncogene. 
(Vannucci et al. 2013.) In 2000, it was reported that children suffering from a fatal form of SCID 
had been cured with retroviral gene therapy (Cavazzana-Calvo et al. 2000). Sadly, after the 
initial promising results, acute leukemias occurred in four of the nine patients. It was found that 
the transgene had integrated in proximity to different proto-oncogenes, leading to uncontrolled 
division of T cells and consequent leukemia. (Hacein-Bey-Abina et al. 2008, Hacein-Bey-Abina 
et al. 2003.) This tragedy prompted efforts to target the integration of transgenes to 
predetermined genomic areas (Wirth, Parker & Yla-Herttuala 2013).  
In the case of proangiogenic gene therapy, the most commonly used vectors are adenoviruses 
and plasmids, which express the transgene transiently and do not integrate into the host 
genome. More than 1000 patients have taken part in angiogenic gene therapy trials over the 
years and so far no major adverse effects have been reported. (Gupta, Tongers & Losordo 2009.) 
However, only a few long-term follow-up studies have been conducted. After the Kuopio 
Angiogenesis Trial (KAT), patients were followed for eight years and no increases in the 
incidence of cardiovascular events or other diseases were detected in patients receiving 
adenoviral VEGF-A therapy as compared to placebo (Hedman et al. 2009). Similarly, in a 10-
year follow-up study of patients receiving a local AdVEGF-A GT into an ischemic lower limb, 
the incidence of cancer, diabetes and retinopathy did not differ between the treatment and the 
control groups (Muona et al. 2012). 
One other aspect that needs to be considered in regard to safety of gene therapy is the 
transgene and its possible harmful effects. VEGF-C and VEGF-D, the factors that have been 
studied in this thesis, have been implicated in tumor formation and metastasis (Karkkainen et 
al. 2009, Hirakawa et al. 2007, Ishii et al. 2004, Skobe et al. 2001). Over-expression of VEGF-C 
has been shown to induce tumor reactive lymphadenopathy, which means that the lymphatic 
networks within the lymph node were enlarged even before the onset of metastasis, most likely 
facilitating the spreading of tumor cells (Hirakawa et al. 2007). Apart from tumor 
lymphangiogenesis, the proteolytically processed forms of VEGF-C and VEGF-D may 
contribute to tumor angiogenesis by binding VEGFR-2, as they have been shown to induce 
angiogenesis in many pathological settings, including cancer (Achen, Stacker 2008). However, 
normal lymph nodes constantly produce low levels of VEGF-C, and in the model used in this 
thesis, only transient over-expression of VEGF-C or VEGF-D is induced in the lymph node as a 
result of the adenoviral delivery (Saaristo et al. 2012). Nonetheless, for patient safety, it would 
be crucial to screen potential recipients of this kind of therapy very carefully, particularly since 
they often are individuals with a history of malignant disease. Thus far, no promotion of 
spontaneous tumor growth has been reported after therapeutic delivery of lymphangiogenic 
growth factors in experimental models. 
 
2.6 PRECLINICAL AND CLINICAL STUDIES 
2.6.1 Preclinical studies of lymphedema 
Lymphedema has been previously studied mostly in small animal models, although some large 
animal studies exist as well (Baker et al. 2010, Blum et al. 2010, Tammela et al. 2007, Yoon et al. 
2003, Szuba et al. 2002, Saaristo et al. 2002b, Karkkainen et al. 2001). The most widely used 
lymphedema animal models comprise the canine hind limb model, the rabbit ear model, the 
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rodent limb model and the rodent tail model; in all of these models lymphedema is induced by 
a surgical procedure and in some cases, additional irradiation. However, all of the 
aforementioned models suffer from some major disadvantages. The previously used canine 
models demanded complex procedures, a long latency time before chronic lymphedema 
developed, and all in all they would be considered unethical today. Small animal models are 
appropriate for molecular studies, but do not sufficiently resemble the conditions encountered 
in human lymphedema, thus casting doubts about their clinical translation to the therapy of 
human patients. (Hadamitzky, Pabst 2008.) The major hurdle in the development of successful 
animal models has been the inability to replicate the chronic disease in a stable, reproducible 
format (Shin, Szuba & Rockson 2003). 
Recombinant VEGF-C, naked plasmid VEGF-C and adenoviral VEGF-C have all been shown 
to induce the growth of functional lymphatics and to ameliorate lymphedema in mice, rabbits 
or sheep (Baker et al. 2010, Cheung et al. 2006, Yoon et al. 2003, Szuba et al. 2002, Karkkainen et 
al. 2001). VEGF-C or VEGF-D in conjunction with lymph node transfer has helped rebuild the 
vascular anatomy after lymph node excision, reduce lymphedema, and even reconstitute the 
immunological barrier function of the transferred lymph nodes in a mouse model of 
lymphedema (Tammela et al. 2007). Recently, the approach of combining autologous lymph 
node transfer with the application of exogenous VEGF-C was further investigated in rats, with 
promising results regarding transplant regeneration and recovery of the lymphatic integrity 
(Schindewolffs et al. 2014, Sommer et al. 2012). Apart from VEGFs, other therapeutic agents 
used to treat secondary lymphedema in the experimental setting have included retinoic acids, 
anti-inflammatory drugs such as ketoprofen, as well as combined autologous bone marrow 
stromal cell and VEGF-C protein injections (Choi et al. 2012, Zhou et al. 2011, Nakamura et al. 
2009). As yet, there are no clinical studies of gene therapy for lymphedema. 
 
2.6.2 Preclinical studies of proangiogenic therapy for PAD  
In the context of cardiovascular diseases, proangiogenic therapies for the revascularization of 
tissues have been studied in animal models of myocardial and peripheral ischemia. In the most 
commonly used animal models of peripheral ischemia, ischemia is induced by ligation, excision 
or ameroid constriction of a large artery in  the hindlimb of a mouse, rat or rabbit (Limbourg et 
al. 2009, Tang et al. 2005, Rissanen et al. 2005, Masaki et al. 2002, Baffour et al. 2000). Several 
proangiogenic factors have been tested using these models, including VEGFs, members of the 
FGF family, HIF-1α, and HGF (Dragneva, Korpisalo & Yla-Herttuala 2013). Both plasmid and 
adenoviral gene transfers of VEGF-A resulted in angiogenesis, increased muscle perfusion, and 
the formation of collateral arteries in ischemic rabbit hind limbs (Korpisalo et al. 2008a, 
Rissanen et al. 2005, Takeshita et al. 1996). Furthermore, AdVEGF-A gene transfer induced 
positive effects on tissue energy metabolism and exercise tolerance in ischemic rat hind limbs 
(Gowdak et al. 2000). However, local VEGF-A gene transfer has been demonstrated to evoke 
unfavorable effects as well, such as increased vascular permeability, edema, and disorganized, 
immature vascular structures (Karvinen et al. 2011, Weis, Cheresh 2005, Lee et al. 2000). 
Therefore, combinations of growth factors and factors modulating the expression of multiple 
downstream targets, such as HIF-1α, have been evaluated in attempts to elicit more 
physiological angiogenesis (Vincent, Feron & Kelly 2002). Increased angiogenesis and muscle 
perfusion were observed in ischemic rabbit hind limbs following an injection of naked DNA 
encoding HIF-1α (Vincent et al. 2000). Adenovirally delivered, constitutively active HIF-1α 
promoted collateral vessel formation and improved tissue perfusion in ischemic rabbit hind 
limbs (Li et al. 2011, Patel et al. 2005). In contrast to VEGF-A, HIF-1α delivered via AAV did not 
result in vascular leakiness in transduced normoxic mouse skeletal muscles (Pajusola et al. 
2005). Importantly, HIF-1α was found to induce marked capillary sprouting in the non-ischemic 
muscles, whereas VEGF-A only induced endothelial proliferation without the formation of 
proper capillary structures (Pajusola et al. 2005). It has been claimed that the approach of 
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inducing angiogenesis at its onset by utilizing hypoxia-induced signaling would harness the 
innate mechanism that naturally generates angiogenesis in physiological as well as pathological 
states (Hadjipanayi, Schilling 2013). 
 
2.6.3 Clinical studies of proangiogenic therapy for PAD  
The first effort to treat PAD in a human patient was made in 1996 with the administration of 
plasmid DNA encoding VEGF-A (Isner et al. 1996). In a randomized, double-blind, placebo-
controlled study conducted in patients with PAD manifesting as claudication and critical limb 
ischemia, intravascular delivery of adenoviral or plasmid liposome VEGF-A resulted in a 
significant increase in vascularity but not in any significant clinical improvements in 
comparison to controls (Makinen et al. 2002). Dose-dependent peripheral edema was observed 
in patients receiving intramuscular injections of low-dose or high-dose VEGF-A, providing 
evidence for bioactivity of adenoviral VEGF-A. Disappointingly, the efficacy end points, such as 
ABI, claudication onset time, and quality-of-life measures, showed no improvement following 
administration of AdVEGF-A. (Rajagopalan et al. 2003.) In another trial of intramuscularly 
administered plasmid VEGF-A, somewhat more promising results were obtained, as VEGF-A 
treated patients experienced fewer amputations, better skin ulcer healing, and hemodynamic 
improvement in comparison with controls (Kusumanto et al. 2006). Plasmid VEGF-A165 
(Neovasculgen®) was approved for the treatment of PAD in Russia in 2011 
(http://www.genetherapynet.com/january-2012.html). Intramuscular administration of AdHIF-
1α has resulted in a good safety profile, pain relief and ulcer healing in a small trial of 38 PAD 
patients, but a larger trial of 289 patients with intermittent claudication revealed no differences 
in peak walking time (exercise treadmill test), claudication onset time, ABI, or quality-of-life 
measurements between HIF-1α and placebo groups (Creager et al. 2011, Rajagopalan et al. 
2007). A meta-analysis derived from a total of 12 randomized, controlled trials of proangiogenic 
gene therapy for PAD detected no benefit from gene therapy for all-cause mortality, 
amputations, or ulcer healing (Hammer, Steiner 2013). 
Several explanations have been offered as to why angiogenic gene therapy clinical trials have 
failed to produce evidence of benefit despite ample, encouraging preclinical data. The animals 
used in preclinical models are usually healthy, whereas patients are typically older. Older 
people may exhibit deficiencies in the recruitment of angiogenic cells and growth factor 
expression, and often suffer from multiple comorbidites, which may impede the response to 
ischemia. (Gupta, Tongers & Losordo 2009.) It has been proposed that the age-dependent 
reduction in VEGF-A expression may be attributable to reduced HIF-1 activity, which would 
explain the impairment in angiogenesis in the elderly (Bosch-Marce et al. 2007, Rivard et al. 
2000). Other factors possibly accounting for the modest results obtained from clinical trials 
include inadequate dosing of the therapeutic drug, insufficient duration of exposure to the 
angiogenic agent, compromised delivery and poor vector transduction efficiency. In addition, 
the obvious differences between animals and humans with respect to physiology, body size, 
and the distance which collateral arteries or lymphatics need to span, should be taken into 
account. (Dragneva, Korpisalo & Yla-Herttuala 2013.) Thus, before embarking on clinical trials, 
it is essential that the therapeutic agent should be evaluated in a large animal model to support 
data obtained from small rodents. 
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3 Aims of the Study 
 
The aim of this thesis was to study the potential of two adenovirally delivered single growth 
factors, VEGF-C and VEGF-D, to achieve therapeutic lymphangiogenesis for the treatment of 
lymphedema, and furthermore, instead of administering only a single growth factor, to study 
the potential of influencing several angiogenic growth factors via adenoviral over-expression of 
HIF-1α/-2α in the treatment cardiovascular diseases. Moreover, the aim was to evaluate 
whether adenovirally induced, transient over-expression of growth factors would be sufficient 
to result in measurable functional improvements, such as improved lymphatic flow and 
enhanced energy metabolism in ischemic tissue in large animal models. 
 
The specific aims of each study were as follows: 
 
I To develop a novel large animal model of lymphedema which would better 
resemble the condition in human patients, and, then to use this model to test the 
possibilities of adenoviral VEGF-C and VEGF-D gene transfers in the induction of 
lymphangiogenesis to improve lymphatic flow. 
 
II To optimize adenoviral VEGF-C gene transfer in the large animal model of 
lymphedema for prospective clinical translation.  
 
III To compare the angiogenic effects of a single adenovirally delivered growth factor, 
VEGF-A, to the effects of adenoviral HIF-1α/-2α, which activate several 
proangiogenic growth factors, in normoxic and ischemic rabbit hindlimbs as well as 
in normoxic mouse myocardium. 
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4 Materials and Methods 
4.1 ANIMAL MODELS 
A total of three animal models were used in this thesis: a novel pig model of lymphedema 
(Studies I and II), a previously developed model of rabbit hindlimb ischemia (Study III) 
(Rissanen et al. 2003a), and a murine myocardium model, where gene transfer was performed 
into the normoxic cardiac muscle of a mouse (Study III). All animal experiments were approved 
by the National Animal Experiment Board of Finland. 
 
4.1.1 Pig model of lymphedema (I-II) 
As a continuation to previous small animal models of lymphedema, a novel large animal model 
was developed which would better resemble the features of lymphedema in human patients, 
such as the distance which lymphatic neovessels need to span and the volume of edema 
formation. The model was used in this thesis to test the lymphangiogenic potential of AdVEGF-
C and AdVEGF-D in combination with autologous lymph node transfer. After anesthetizing the 
pigs, the normally invisible lymphatic vessels of the inguinal area were rendered visible to the 
naked eye by the Patent Blue (Guerbet) tracer dye. To block lymphatic drainage from the lower 
limbs, the lymphatic vasculature surrounding the inguinal lymph node was damaged 
surgically, leaving the blood vascular pedicle intact to simulate microsurgical anastomosis of 
blood vessels to the lymph node (Figure 8A). Next, gene transfer was performed as described 
later, after which the pedicular lymph node was attached into the remaining tissue 4 cm lateral 
from its original position. This procedure mimicks lymph node transfer in human lymphedema 
patients in that the lymph node is vascularized but lacks all lymphatic connections. The animals 
were followed for 2 or 6 months postoperatively. The sizes of the transferred lymph nodes as 
well as those of unoperated contralateral lymph nodes were measured in three dimensions at 
euthanasia which occurred 2 months after the surgical procedure. In addition, samples from 
internal organs (heart, lung, liver, kidney, spleen, gonads) were collected for safety examination 
(I). 
 
4.1.2 Rabbit model of hind limb ischemia (III) 
A rabbit model of acute hind limb ischemia was used to study the angiogenic and metabolic 
effects of AdHIFs in peripheral muscles. To induce ischemia in the calf region, the superficial 
part of the femoral artery was excised (Figure 8B). Additionally, two re-entry branches were 
ligated to block collateral growth from the lateral circumflex and deep femoral arteries. As a 
result, the calf region became severely ischemic but the thigh remained normoperfused. The 
animals were euthanized 7 days after the procedure and 6 days after GT. 
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Figure 8. A, The pig model of lymphedema and autologous lymph node transfer. The afferent and 
efferent lymphatic vessels surrounding the inguinal lymph node were excised, leaving only the main 
artery and vein supplying the node intact. Gene transfer was made either intranodally under the 
capsule of the node or perinodally into the fat surrounding the node. Reprinted by permission from 
Ann Surg.: May 2013 - Volume 257(5) - p 961-967, Wolters Kluwer Health Lippincott Williams & 
Wilkins ©. B, The rabbit model of hindlimb ischemia. The superficial femoral artery and two re-entry 
branches were ligated to induce ischemia in the calf region. Black bars mark ligations. Adapted with 
permission from Johanna Lähteenvuo © 2001. 
 
4.2 GENE TRANSFER METHODS 
Human clinical grade first generation serotype 5 replication deficient (E1, partial E3-deletion) 
adenoviruses produced under GMP conditions in 293 cells were used as gene transfer vectors 
throughout the studies. All of the used viruses have the cytomegalovirus (CMV) promoter. The 
functionality of the viral constructs was tested in vitro before using them in animal experiments. 
 
4.2.1 Intranodal and perinodal gene transfers (I-II) 
Intranodal gene transfer was performed under the capsule of the inguinal lymph node of pigs 
with a series of injections using a needle and a syringe (I, II) (Figure 8A). Perinodal gene 
transfer was conducted in a similar manner into the fat surrounding the lymph node (II) (Figure 
8A). A total dose of 1 x 1011 viral particles (vp) encoding full-length VEGF-C, full-length VEGF-
D, or control gene β-galactosidase (LacZ) was injected per animal (I,II). In addition, a lower 
dose of 1 x 1010 vp encoding full-length VEGF-D was administered for a subset of animals (I). 
Gene transfer was performed immediately after the surgical excision of lymphatic vessels. 
 
4.2.2 Intramuscular gene transfer (I, III) 
Intramuscular gene transfer was performed by manual injections into the hindlimb skeletal 
muscles of New Zealand White rabbits using a needle and a syringe (III). Adenoviruses 
encoding the stabilized forms of mouse HIF-1α and HIF-2α were used as therapeutic drugs, 
AdLacZ as a negative control virus, and AdVEGF-A as a positive control virus. A dose of 1 x 
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1011 vp was injected into the non-ischemic semimembranosus muscles, whereas in ischemic 
hindlimbs, a total dose of 3 x 1011 vp was administered to the whole hindlimb covering the 
semimembranosus, quadriceps femoris, abductor cruris cranialis and tibialis anterior muscles. 
Gene transfer into ischemic muscles was performed 1 day after the ischemia procedure.  
Intramuscular gene transfer was also performed on the right hind limbs (m. gastrocnemius) 
of C57/Bl/6J mice (I). The mice received a dose of 5 x 108 plaque-forming units (pfu) of AdVEGF-
C, AdVEGF-D, or AdLacZ.  
 
4.2.3 Myocardial gene transfer (III) 
Adenoviruses encoding HIF-1α, HIF-2α, and LacZ were used for echocardiography-guided 
myocardial gene transfers in C57Bl/6J mice. Following induction of isoflurane inhalation 
anesthesia, 1 x1010 viral particles in a volume of 10 μL were injected into the anterior wall of of 
the left ventricle as described previously (Huusko et al. 2010, Springer et al. 2005). 
 
4.3 X-RAY IMAGING  
X-ray radiography was used in all of the studies either to assess the growth of collecting 
lymphatic neovessels in pigs (I,II) or collateral artery formation in rabbits (III). 
 
4.3.1 Lymphangiography (I-II) 
X-ray lymphangiographies were recorded with Siemens Siremobil 3000 C-arm (I) or Innova 
3100 IQ Excellence X-ray machine (GE Healthcare) (II) from the inguinal region of pigs before 
and after the excision of lymphatics (Figure 9), and at the time of euthanasia. Lipiodol (Guerbet) 
served as a radio-opaque contrast agent. Lymphangiograms were used perioperatively to 
confirm that the lymphatic defect was of a standard width, as well as to evaluate the therapeutic 
effect of gene transfers after a predetermined follow-up period of 2 or 6 months. For this, the 
numbers of Lipiodol-positive lymphatic vessels connecting to and draining past the lymph 
node were quantified from still images and dynamic X-ray sequences (30 fps, frames per 
second). 
 
4.3.2 Digital subtraction angiography (III) 
Digital subtraction angiography (DSA) is a type of fluoroscopy technique that permits the 
visualization of vascular structures without superimposed bone and soft tissue densities. 
Images of blood vessels are produced by subtracting a pre-contrast image from subsequent 
images taken with contrast medium. In this thesis, DSA was used to visualize collateral blood 
vessel formation following gene transfer into ischemic rabbit hindlimbs. A 5 French catheter 
(Cordis) was introduced into the abdominal aorta of rabbits for the injection of contrast agent 
(Hexabrix, Guerbet). Serial DSA images (30 fps) were recorded immediately after the injection 
of contrast agent bolus with Innova 3100 IQ Excellence X-ray machine. Collateral vessel 
numbers and diameters were quantified from images with the best arterial filling. 
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Figure 9. Perioperative lymphangiograms before and after lymphatic vessel excision. Arrows mark 
excision sites and the asterisk shows the lymph node. Reprinted by permission from Ann Surg.: May 
2013 - Volume 257(5) - p 961-967, Wolters Kluwer Health Lippincott Williams & Wilkins ©. 
 
4.4 ULTRASOUND IMAGING  
Ultrasound imaging was used to evaluate the effects of gene transfer on mouse myocardium 
and rabbit skeletal muscle (III). Myocardial imaging was performed as described previously 
(Huusko et al. 2010) with a high-resolution imaging system (Vevo 770, VisualSonnics Inc) using 
a high-frequency ultrasound probe (RMV-707B) on the day of the GT and 6 days after GT. The 
determined parameters included ejection fraction (EF%) and left ventricle anterior wall 
thickness (LVAW; mm).  
Native Doppler ultrasound and contrast pulse sequence (CPS) imaging performed with 
Acuson Sequoia 512 (Siemens) were used to assess perfusion in gene-transduced hindlimb 
muscles of rabbits. CPS is a rather new ultrasound perfusion imaging technique associated with 
better spatial resolution and tissue penetration than previous perfusion imaging modalities, and 
has proven to provide an accurate evaluation of real-time perfusion in small laboratory animals 
(Rissanen et al. 2008, Phillips, Gardner 2004). A 0.5 mL bolus of SonoVue (Bracco) contrast 
microbubbles was administered via the ear vein and transversal images of semimembranosus 
muscles were captured immediately thereafter. Imaging was performed one day after ischemia 
procedure and six days after GT. 
Skeletal muscle perfusion was also measured during physical activity. In that assessment, the 
sciatic nerve was electrically stimulated for 6 minutes to induce maximal contraction in the calf 
muscles. Perfusion imaging was performed after the stimulation ceased. The signal intensities 
were quantified with DataPro software (version 2.13, Noesis). 
 
4.5 31P-MAGNETIC RESONANCE SPECTROSCOPY 
31Phosphorus-magnetic resonance spectroscopy (31P-MRS) is an established method for the 
assessment of metabolic correlates of tissue perfusion and was employed as a time-dependent, 
non-invasive measurement of changes in muscle metabolites, i.e. phosphocreatine (PCr) and 
inorganic phosphate (Pi), during rest, exercise and recovery from exercise (III) (Gowdak et al. 
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2000). At the beginning of exercise, hydrolyzed ATP is resynthesized from PCr breakdown. 
Thus, PCr decreases and Pi increases, while ATP levels remain constant (Figure 10). During 
recovery, PCr is restored and Pi levels normalize. (Prompers et al. 2006.) The ratio of PCr to Pi 
(PCr/(PCr+Pi)) can be used to assess the energy balance of the muscle (Korpisalo et al. 2008b).    
31P-MRS was performed on ischemic rabbit skeletal muscles before GT and 6 days after GT 
with a UNITYINOVA imaging console (Varian) as described previously in detail (Korpisalo et al. 
2008b). Physical activity in the muscles was achieved through stimulation of the sciatic nerve in 
a similar manner as during ultrasound imaging. Muscle recovery was followed for 12 minutes 
with 31P-MRS after the cessation of stimulation. The PCr/(PCr+Pi) ratios were calculated and 
used as a measure of aerobic capacity and recovery rate. 
 
            
 
Figure 10. Representative 31P-MRS spectra of normoxic and ischemic muscles during rest, exercise 
and recovery. At rest, high PCr and ATP peaks are visible. During exercise, PCr decreases and Pi 
peaks. PCr reservoirs are then replenished during recovery. In ischemic muscles, the high Pi peak 
and low PCr during exercise indicate a shift towards anaerobic metabolism. Korpisalo et al., 
“Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic 
rabbit hindlimbs”, Cardiovasc Res., 2008, 1;80(2):263-70, by permission of Oxford University Press. 
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4.6 VASCULAR PERMEABILITY AND TISSUE EDEMA 
 
4.6.1 Seroma fluid evaluation (I-II) 
To evaluate the amount of seroma fluid that accumulated in the operated area of pigs following 
the excision of lymphatic vessels, an observer blinded to the study groups visually estimated 
the volume of fluid collection in deciliters every day for 2 weeks (I) or until the edema had 
dissipated (II). The seroma sacs were drained with a needle in case the volume was deemed 
harmful for the well-being of the animal. 
 
4.6.2 Modified Miles Assay (I, III) 
Extravasation of plasma proteins and the leakiness of neovessels in rabbit transduced muscles 
were assessed by modified Miles Assay (III) (Rissanen et al. 2003a). Evans Blue (Sigma Aldrich) 
dye, which binds mostly to plasma albumin, was injected intravenously 30 minutes before 
sacrifice. Following sacrifice, the animals were perfusion fixed with 1% paraformaldehyde in 
citrate buffer (pH 3.5) to rinse off the remaining dye from the blood vessels. The extravasated 
dye from muscle samples was then eluted in formamide, after which it was quantified with a 
spectrophotometer at a wavelength of 610 nm. 
Modified Miles Assay was also performed in C57/Bl/6J mice receiving a gene transfer of 
AdVEFG-C, AdVEGF-D, or AdLacZ to determine the effects of VEGF-C and VEGF-D on 
vascular permeability (I). 
 
4.7 PROTEIN ANALYSES 
 
4.7.1 Western Blot (I, III) 
Seroma fluid samples were collected from pigs 11 days after excision of lymphatics and snap 
frozen in liquid nitrogen (I). To assess the amount of VEGF-C and VEGF-D in seroma fluid, 
Western Blot protein expression analysis was performed with antibodies against VEGF-D (AF-
286, R&D Systems) and VEGF-C (AF-752, R&D Systems). Horseradish-peroxidase-conjugated 
Donkey anti-goat IgG (Santa Cruz Biotechnology) served as a secondary antibody. The blots 
were scanned, and densitometric ratios of short isoforms of growth factors versus full-length 
isoforms were quantified with Adobe Photoshop CS4. 
AdHIF-1α and AdHIF-2α constructs were tested with Western Blot for their protein 
production in vitro prior to their usage in vivo (III). Monoclonal antibodies against HIF-1α 
(NB100-123, Novus Biologicals) and HIF-2α (NB100-132, Novus Biologicals) were used. 
 
4.7.2 ELISA (I) 
The enzyme-linked immunosorbent assay (ELISA) was performed to test the in vitro protein 
production of AdVEFG-C and AdVEGF-D. Human umbilical vein endothelial cells (HUVECs) 
were transduced with AdVEGF-C, AdVEGF-D or AdLacZ. Cell culture media were harvested 
72 hours after transduction, and VEGF-C and VEGF-D protein levels were measured from these 
media with the appropriate ELISA kits (DVEC00 and DVED00, respectively, R&D Systems). 
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4.8 mRNA EXPRESSION 
Quantitative PCR was used to verify the expression of mouse HIF-1α and HIF-2α mRNA in 
transduced rabbit hindlimb muscle (III). Total RNA was extracted from snap-frozen muscle 
samples with an appropriate commercial kit (RNeasy Fibrous Tissue Midi Kit, #75742,  Qiagen) 
and cDNA was synthetized from 2 μg of total RNA using random primers (Promega). 
Expression levels of HIF-1α and HIF-2α mRNA were measured with StepOnePlusTM Real-Time 
PCR System (Applied Biosystems). 
Quantitative PCR was also used to examine the in vitro upregulation of HIF target genes 
VEGF-A and PDK1 (III). HUVECs were transduced with AdHIF-1α, AdHIF-2α, AdLacZ, or an 
empty adenovirus vector (AdCMV). Fortyeight hours after transduction, the cells were lysed in 
TriReagent (Invitrogen), RNA was isolated with chloroform, and cDNA was synthesized. 
VEGF-A and PDK1 mRNA levels were measured with StepOnePlusTM Real-Time PCR System. 
 
4.9 IMMUNOHISTOCHEMISTRY AND HISTOLOGY 
Immunohistochemical stainings were used to evaluate lymphangiogenesis (I, II), angiogenesis 
(I, III), inflammatory cell numbers (I, II), and the expression of specific proteins (HIFs, VEGF-A, 
eNOS) (III).  Hematoxylin-eosin stainings were used to characterize the tissue morphology (I-
III). All the stainings were performed on sections cut from paraffin embedded tissues. The 
avidin-biotin HRP (horseradish peroxidase) system with diaminobenzidine (DAB; Vector 
Laboratories) and the alkaline phosphatase system with Vector Blue (Vector Laboratories) were 
used for signal detection. The antibodies used are listed in table 3 and the protocols are 
described or referenced in the original publications. 
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Table 3. Antibodies used in immunohistochemistry 
 
Antibody Structure stained Dilution Pretreatment Manufacturer Study 
PECAM-1 endothelium (pig) 1:100 - R&D Systems I 
CD31 endothelium (rabbit) 1:50 - DAKO III 
Griffonia 
simplicifolia 
lectin I 
endothelium (mouse) 1:100 - Vector Laboratories III 
α-SMA smooth muscle cells, pericytes 1:250 - Sigma Aldrich I 
LYVE-1 lymphatic endothelium 1:100 - R&D Systems I 
PROX-1 lymphatic endothelium 1:100 
Citrate buffer 
boiling, TSA R&D Systems I 
VEGFR-3 lymphatic endothelium 1:100 
Citrate buffer 
boiling 
non-commercial 
(Jussila et al. 1998) II 
CD3 T cells 1:25 Target Retrieval Solution (DAKO) DAKO I, II 
CD20cy B cells 1:200 Target Retrieval Solution (DAKO) DAKO I, II 
CD23 Dendritic cells 1:10 Target Retrieval Solution (DAKO) DAKO I, II 
HAM56 Macrophages 1:100 - DAKO II 
HIF-1α HIF-1α 1:250 - Novus Biologicals III 
HIF-2α HIF-2α 1:250 - Novus Biologicals III 
VEGF-A VEGF-A 1:250 - Santa Cruz Biotechnology  III 
eNOS eNOS 1:50 - BD BioSciences III 
TSA = tyramide signal amplification 
 
To evaluate lymphatic and blood vessel growth from the immunostainings, mean 
capillary/vessel areas (μm2), capillary/vessel perimeters (μm), and numbers of 
capillaries/vessels were quantified with AnalySIS software (Soft Imaging System) from the 
microscopic images (Olympus AX-70) of  VEGFR-3-, PROX-1 + α-SMA-, PECAM-1 + α-SMA-, 
CD31- and lectin-stained sections (I-III). In addition, the numbers of inflammatory cells inside 
the lymph nodes were counted from sections stained for B cells, T cells, dendritic cells (I, II) and 
macrophages (II). The stage of lymph node atrophy following disruption of lymph flow to the 
node was evaluated from the hematoxylin-eosin stained specimens (I, II). 
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4.10 ASSESSMENT OF LYMPHATIC FUNCTION 
The functionality of the lymphatic neovessels was evaluated from Lipiodol X-ray 
lymphangiograms as described in chapter 4.3.1 (I, II) and by an adaptation of the modified 
Miles assay (I). In the modified version of the assay, a mix of Patent Blue and Evans Blue dyes 
was injected distally into the pig hindlimb and serum samples were collected 13 minutes after 
the injection. The marker dyes were then eluted from the serum in formamide, and their 
amounts quantified with a spectrophotometer. The assay is based on the expectation that the 
lymphatic neovasculature in the operated area will collect the dye and transport it to the 
systemic circulation. Thus, the more dye there is in the collected serum samples, the better is the 
lymph flow in the operated area. 
4.11 STATISTICAL ANALYSES 
Results are expressed as means ± standard deviation (SD) (I, II) or means ± standard error of 
mean (SEM) (III) for normally distributed data, and medians with interquartile ranges for non-
normally distributed data (II). The normality of distribution was assessed visually by plotting 
data from individual experiments to a quantile (Q-Q) plot and residuals of data to a histogram. 
Data estimated to approximately follow normal distribution were tested using parametric tests. 
The independent-samples Student’s t-test was used when comparing only two groups against 
each other.  For comparing multiple groups, the one-way analysis of variance (ANOVA) was 
performed, and in the case of a statistical significance, followed by Dunnett’s Multiple 
Comparison test or Tukey’s Multiple Comparison test, or pairwise comparison and Bonferroni 
correction for multiple comparisons. Two-way ANOVA for repeated measures with 
Bonferroni’s post hoc test was used when comparing multiple groups with two independent 
variables. In case of non-normally distributed data, the nonparametric analysis of variance 
(Kruskal-Wallis) was performed, followed by the Mann-Whitney U test for pairwise 
comparison and the Bonferroni adjustment for multiple testing. Linear mixed-effect models 
were used to analyze group differences at baseline and during follow-up in the evaluation of 
seroma fluid accumulation (I, II). Benjamini-Hochberg false discovery rate was used to adjust 
results for multiple comparisons. Throughout, corrected p-values of < 0.05 were considered 
statistically significant.  
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5 Results 
5.1 THERAPEUTIC LYMPHANGIOGENESIS FOR LYMPHEDEMA (I) 
Therapeutic lymphangiogenesis in the form of adenoviral VEGF-C and VEGF-D gene transfers 
was studied in a novel pig model of lymphedema. The inguinal lymphatic vascular network 
was destroyed and adenovirally over-expressed therapeutic genes were administered into the 
lymph node with an intact vascular pedicle simulating microvascular anastomosis of 
transferred lymph nodes. AdLacZ served as control. 
 
5.1.1 Lymphatic vessel regrowth induced by AdVEGF-C and AdVEGF-D  
The numbers of collecting lymphatic vessels detectable by Lipiodol x-ray lymphangiography 
were counted 2 months after lymphatic vessel excision and gene transfer. Both AdVEGF-C and 
AdVEGF-D induced a statistically significant increase in the number of functional lymphatic 
vessels spanning the operated area as compared to the AdLacZ control group (Figure 11A). 
Most of the lymphatic neovessels were connected to the lymph node, although vessels 
bypassing the node were also detected in many animals regardless of the given treatment.  
Prominent lymphatic vessel growth following AdVEGF-C and AdVEGF-D GT was observed 
in lymph node tissue sections stained for LYVE-1 (lymphatic capillaries) (Figure 11B-D). Dense 
LYVE-1 positive lymphatic capillary networks were concentrated around the pericapsular area 
in AdVEGF-C-treated pigs, and in the connective tissue surrounding the lymph node in 
AdVEGF-D treated pigs. The numbers of PROX-1 + α-SMA positive vessels (collecting 
lymphatic vessels) were higher in both the AdVEGF-C (157 ± 41, P < 0.01) and AdVEGF-D 
groups (134 ± 36, p < 0.05) than in the AdLacZ group (75 ± 22). 
As a consequence of the reconstituted lymphatic connections to the lymph node, the lymph 
node structure, as evaluated from the hematoxylin-eosin staining, was better preserved in the 
AdVEGF-C and AdVEGF-D groups than in the control group (Figure 11E). Hematoxylin-eosin 
staining of the lymph nodes revealed that the normal follicular structure was retained in most 
of the AdVEGF-C and AdVEGF-D transduced lymph nodes, whereas control lymph nodes had 
been more often infiltrated with adipose and connective tissue, as well as groups of 
lymphocytes and siderophages detected mainly around vessels (Figure 11F-H). 
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Figure 11. A, The numbers of lymphatic vessels in the inguinal area 2 months after the procedure as 
counted from Lipiodol lymphangiograms. B-D, LYVE-1 immunostaining revealing robust 
lymphangiogenesis characterized by dilated sinuses in the AdVEGF-C-treated lymph nodes and more 
discrete lymphangiogenesis in the AdVEGF-D-treated lymph nodes. E, Quantification of the amount 
of connective and adipose tissue in the lymph node sections. F-H, Hematoxylin-eosin staining of the 
lymph nodes. The asterisk in G points to the slight deterioration of the nodal tissue, and the 
asterisks in H point to the grouped lymphocytes and siderophages. Magnifications: B,C,D,F,G: 
12,5X; H: 100X. ** = p < 0.01, *** = p < 0.001. 
 
5.1.2 Lymphatic transport 2 months after AdVEGF-C and AdVEGF-D treatment 
The lymphatic neovessels detected by lymphangiography mainly in the AdVEGF-C- and 
AdVEGF-D-treated animals carried Lipiodol contrast agent in a distal-to-proximal direction, 
thus indicating restored lymphatic flow in the operated area (Figure 12A-C). To further assess 
improvement in lymph transport across the damaged area, the accumulation of Evans Blue + 
Patent Blue dye mix in the systemic blood following distal injection of the dyes was quantified. 
AdVEGF-C and AdVEGF-D increased dye transport into the systemic circulation by 50% and 
40%, respectively, as compared to AdLacZ controls (Figure 12D). 
  
       
 
Figure 12. A-C, Lipiodol lymphangiograms of the inguinal area 2 months after operation with 
arrowheads pointing to lymphatic neovessels and asterisks marking the lymph nodes. D, 
Quantification of the accumulated Patent Blue + Evans Blue dyes in the systemic blood after a dye 
mix injection distal to the lymphatic excision site. *** = p < 0.001. 
53 
 
 
5.1.3 Increased seroma formation following AdVEGF-D gene transfer 
The surgical excision of lymphatic vessels led to an immediate accumulation of seroma fluid in 
the inguinal ring area. During follow-up, the volume of seroma was visually estimated by an 
observer blinded to the study groups. The amounts of seroma in each treatment group 
increased at a similar rate for the first 6 days after the surgical procedure (Figure 13A). On the 
7th day postoperation, the curve depicting the volume of seroma in the AdVEGF-D treatment 
group started to diverge upwards from those of the AdVEGF-C and the AdLacZ groups. 
Seroma fluid volumes in the AdVEGF-D-treated animals continued to rise for the remainder of 
the 2-week follow-up period, whereas fluid volumes in AdVEGF-C and AdLacZ groups 
remained low and at comparable levels. Furthermore, AdVEGF-D-treated animals required 
drainage of excessive fluid due to animal welfare considerations, whereas spontaneous 
dissipation of seroma without the need for drainage was observed in the other two groups by 
two weeks after the procedure. 
In an attempt to clarify the causes of the dissimilar seroma fluid buildup between groups, a 
few possible explanations were explored. First, the adenoviral constructs were tested for their 
protein production in HUVEC cells. ELISA analysis of the cell culture media revealed negligible 
differences in protein expression between constructs (Figure 13B). Next, a new set of pigs 
receiving a 10-fold lower dose (1 x 1010 vp) of AdVEGF-D was operated to study whether a 
lower viral dose would reduce seroma formation. However, a similar trend in the seroma fluid 
accumulation was observed as previously with a higher dose of AdVEGF-D (Figure 13A). 
Finally, the proteolytic processing of the administered growth factors was examined in order to 
determine whether angiogenesis and increased vascular permeability known to be induced by 
the processed short forms could be involved in the fluid buildup. For this, a Western Blot 
analysis of collected seroma samples was performed. It was observed that AdVEGF-D animals 
displayed high levels of proteolytically processed human VEGF-D, whereas AdVEGF-C 
animals had only small amounts of processed VEGF-C in their seroma (Figure 13C). A 
subsequent densitometric analysis from the Western Blots showed significantly higher ratios of 
processed versus full-length forms of VEGF-D (0.53 ± 0.11) than VEGF-C (0.30 ± 0.025) in the 
AdVEGF-D and AdVEGF-C transduced animals, respectively, implying that there had been 
increased processing of VEGF-D into its shorter isoform (p = 0.03).  
To investigate potential angiogenic effects of the short isoform of VEGF-D that was found to 
be present in significant amounts in seroma fluid, lymph node sections were immunostained for 
PECAM-1 + α-SMA marking blood capillaries. There was a two-fold increase in mean capillary 
area in AdVEGF-D-treated nodes in comparison to AdLacZ controls (p < 0.05). Furthermore, a 
modified Miles assay performed in C57/Bl/6J mice revealed an almost 9-fold increase in the 
vascular permeability in AdVEGF-D transduced mouse hindlimbs as compared to mice 
receiving AdLacZ (p < 0.001). Extravasation was 3.5-fold higher but not statistically significantly 
higher in AdVEGF-C-treated mice than in control mice. 
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Figure 13. A, Seroma fluid buildup as a function of time. For both AdVEGF-D groups vs. AdLacZ 
p < 0.001. ‘Dr’ marks drainage in AdVEGF-D higher dose group on postoperative day 11 and 13, and 
in AdVEGF-D lower dose group on postoperative day 11. B, ELISA analysis of the in vitro protein 
production of AdVEGF-C and AdVEGF-D constructs. C, Western Blot analysis of VEGF-C and VEGF-D 
proteins in seroma fluid. Upper band represents the full-length form and the lower band is the 
processed short form, P = positive control, L = LacZ, C = VEGF-C, D = VEGF-D. 
 
5.1.4 Histopathological evaluation of safety samples 
Hematoxylin-eosin-stained sections of the collected safety samples (heart, lung, liver, kidney, 
spleen, gonads) were examined by a pathologist. No signs of pathological changes were 
observed in these organs in either of the treatment groups or in the control group when 
examined two months after the procedure. 
5.2 OPTIMIZING ADVEGF-C THERAPY FOR LYMPHEDEMA (II) 
Adenoviral VEGF-C gene transfer was established as a promising lymphangiogenic agent in the 
first study and was therefore selected for further evaluation and optimization of delivery in the 
same pig model of lymphedema as used previously. AdVEGF-C gene transfer under the 
capsule of the lymph node was compared to gene transfer into the fat surrounding the lymph 
node in terms of efficacy and injurious effects. Control animals received injections of AdLacZ or 
saline. 
 
5.2.1 Lymphatic neovessel growth induced by intranodal and perinodal AdVEGF-C  
Lymphatic vessel regrowth in the operated area two months after GT was evaluated from 
lymphangiograms recorded with a new Innova 3100 IQ Excellence X-ray machine with superior 
resolution than that used in the earlier experiment. Dense lymphatic networks and perfused 
lymph nodes were observed in animals treated with AdVEGF-C regardless of whether GT was 
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performed intranodally or perinodally (Figure 14A and C). In control pigs, markedly fewer 
functional vessels were observable, although some isolated lymphatic vessels also spanned the 
damaged area in those animals (Figure 14B, D and E). Lymphangiograms taken from four 
animals at six months after the procedure revealed similar differences in lymphatic vessel 
growth between pigs receiving either intranodal AdVEGF-C or intranodal AdLacZ (Figure 14F 
and G). However, no quantitative comparison could be made at the 6-month timepoint due to 
the small number of animals.  
 
 
Figure 14. Lymphangiogenic effects of intranodally and perinodally administered AdVEGF-C versus 
control groups as illustrated by lymphangiograms taken two (A-E) and six (F-G) months after 
operation and GT. Perfused lymph nodes (asterisk) can be seen in the AdVEGF-C-treated animals. 
Scale bars = 10 mm.  
 
Lymphatic vessels connected to and bypassing the lymph node were counted from the two-
month-timepoint lymphangiograms. The total number of lymphatic vessels and the number of 
lymph node-connected vessels were higher in the intranodal and perinodal AdVEGF-C groups 
than in their respective AdLacZ control groups and saline control group (Figure 15). Some 
lymphatic vessels bypassing the node were observed in most animals but their numbers did not 
differ significantly between the groups. 
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Figure 15. Quantification of lymphatic vessels from the lymphangiograms two months after the 
procedure. *** = p < 0.001, ** = p < 0.01, * = p < 0.05, ns = non-significant. 
 
Lymphangiogenic effects of AdVEGF-C were further examined at the microscopic level from 
VEGFR-3 immunostained sections of lymph nodes and adjacent tissues (Figure 16). Perinodal 
AdVEGF-C gene transfer induced lymphangiogenesis most prominently in the pericapsular 
area and in the connective tissue surrounding the lymph node, whereas intranodal AdVEGF-C 
appeared to stimulate lymphatic capillary growth also inside the lymph node with capillary 
clusters replacing small areas of normal follicular structure. VEGFR-3 positive lymphatic vessel 
lumens in both AdVEGF-C groups were significantly larger than in their respective control 
groups (intranodal VEGF-C vs. intranodal LacZ: p < 0.001; perinodal VEGF-C vs. perinodal 
LacZ: p = 0.001). 
 
 
Figure 16. Robust lymphangiogenic effect in the connective tissue surrounding the lymph node in 
AdVEGF-C-treated animals as visualized by immunohistochemical staining for VEGFR-3. 
Magnification: 100X, scale bars: 100 μm. 
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5.2.2 Effects of intranodal and perinodal AdVEGF-C on lymph node preservation and seroma 
formation 
Lymph nodes were excised and measured in three dimensions after euthanizing the animals 
two months after the procedure. The lymph node sizes in the intranodal LacZ group (12 ± 6 cm3, 
p = 0.009), the perinodal LacZ group (14 ± 7 cm3, p = 0.003), and the saline control group (12 ± 5 
cm3, p < 0.001) were smaller than the nonoperated lymph nodes of the left limb (24 ± 8 cm3). 
Lymph nodes receiving either intranodal (30 ± 7 cm3) or perinodal AdVEGF-C (28 ± 12 cm3) 
retained their original size and exhibited no statistical difference to the intact left side lymph 
nodes. 
Lymph node structure was examined from hematoxylin-eosin-stained sections and atrophy 
was given a grade between 0 and 4, with 0 representing an intact lymph node structure and 4 
representing extensive atrophy. The median values with interquartile ranges for different 
groups were as follows: intranodal AdVEGF-C 1.0 (0.0 - 2.0), perinodal AdVEGF-C 1.0 (1.0 - 
1.5), and NaCl control 3.0 (2.0 - 4.0). In general, local decreases in cellularity and minor fibro-
fatty formations were observed in AdVEGF-C-treated lymph nodes, whereas confluent areas of 
fibro-fatty tissue were found in NaCl control nodes (Figure 17).  
Seroma formation during follow-up was evaluated in a similar manner as in Study I. Despite 
differences in volumes between study groups at certain time points, the overall seroma volumes 
did not differ statistically between groups (p = 0.062). 
 
 
 
 
Figure 17. Hematoxylin-eosin staining of the lymph nodes. Asterisks mark atrophied areas. 
Magnification: 12.5X, scale bars: 100 μm. 
 
5.2.3 Macrophage accumulation inside the lymph node following intranodal GT 
HAM56-antibody was used to label macrophages inside the lymph nodes. Clusters of tingible 
body macrophages were observed in the germinal centers of the intranodally injected lymph 
nodes, whereas fewer macrophages were found lining the subcapsular and trabecular sinuses of 
lymph nodes receiving perinodal GT or saline injections (Figure 18). There were 2.3-fold more 
HAM56-positive cells present in the intranodal AdVEGF-C-treated lymph nodes than in the 
perinodal AdVEGF-C-treated lymph nodes (p < 0.05), and 2.7-fold more in the lymph nodes 
receiving intranodal AdLacZ than in the lymph nodes receiving perinodal AdLacZ (p < 0.01). 
No treatment-related differences were observed in the numbers of B cells, T cells and dendritic 
cells inside the lymph node. 
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Figure 18. Immunohistochemical staining for the macrophage marker HAM56 showing intense 
accumulation of macrophages in the germinal centers of lymph nodes following intranodal 
administration of AdVEGF-C. Arrowheads point out HAM56-positive cells. Magnifications: 12,5X for 
large images, 200X for insets. Scale bars: 100 μm for bigger images, 10 μm for insets. 
 
5.3 THERAPEUTIC ANGIOGENESIS VIA OVER-EXPRESSION OF HIFS (III) 
The effects of transcription factors HIF-1α and HIF-2α on angiogenesis and muscle energy 
metabolism were studied in normoxic and ischemic rabbit hindlimbs, as well as in normoxic 
mouse myocardium. Gene transfer was performed by intramuscular injections. The effects of 
adenoviral delivery of HIFs were evaluated 6 days after GT. AdVEGF-A served as a positive 
control and AdLacZ as a negative control. 
 
5.3.1 Angiogenic response following AdHIF-1α and AdHIF-2α GTs 
Both AdHIF-1α and AdHIF-2α induced enlargement of blood capillaries in rabbit skeletal 
muscles and mouse myocardium, as evidenced by the immunostainings for CD31 and Griffonia 
simplicifolia lectin (Figure 19A-H). The increase in capillary size evoked by AdHIF-1α and 
AdHIF-2α was approximately four-fold in normoxic rabbit hindlimbs and two-fold in normoxic 
mouse myocardium as compared to AdLacZ. AdVEGF-A induced a much more robust 
enlargement of the capillaries, which, on the downside, led to substantial tissue edema and 
vascular leakage that were not associated with AdHIFs. Vascular leakage, as evaluated with the 
modified Miles assay, was 35-fold (p = 0.006) greater in the AdVEGF-A transduced muscles 
than in the intact control muscles. 
Native Doppler and CPS imaging were used to quantify perfusion of the transduced 
normoxic hindlimb muscles at rest (Figure 19I-P). Perfusion measurements revealed a 2- to 5-
fold increase in AdHIF-1α/-2α transduced muscles 6 days after GT compared to AdLacZ. 
AdVEGF-A transduced muscles showed an 18- and 34-fold higher perfusion than controls, as 
determined from CPS and Doppler images, respectively. In ischemic muscles, AdHIF-2α but 
not AdHIF-1α, statistically significantly improved perfusion after physical activity from day 0 
to day 6, as quantified from CPS images.  
Digital subtraction angiography was used to assess collateral artery formation in ischemic 
hindlimbs. AdHIF-1α and AdHIF-2α increased the number of opened collateral vessels as 
compared to AdLacZ, albeit not statistically significantly. The mean diameters of collateral 
vessels were similar between all groups. 
. 
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Figure 19. Effects of AdHIFs and AdVEGF-A on normoxic rabbit skeletal muscles and normoxic 
mouse myocardium. A-D, CD31 staining demonstrating notably enlarged capillaries in AdVEGF-A 
transduced rabbit skeletal muscle and moderate enlargement of capillaries following AdHIF-1α and 
AdHIF-2α GTs. E-H, Similar pattern of capillary enlargement evident in the lectin-stained mouse 
myocardium. I-L, Native Doppler imaging showing blood flow in large vessels of the m. 
semimembranosus. M-P, CPS imaging demonstrating muscle perfusion at the capillary level. 
Asterisks in J and N point to increased tissue edema between m. gracilis and m. semimembranosus 
after AdVEGF-A GT. 
 
 
The effects of AdHIFs on cardiac function in mice were evaluated by ultrasound imaging. 
AdHIF-2α maintained cardiac function at the basal level, as concluded from ejection fraction 
percentages (Figure 20). A decrease in this parameter was observed after AdHIF-1α and 
AdLacZ GT. In contrast, AdHIF-1α was associated with an increased thickness of the left 
ventricle anterior wall at diastole. 
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Figure 20. Parameters depicting left ventricle function in mice before and 6 days after GT. EF% = 
ejection fraction, LVAW;d = left ventricle anterior wall thickness. * = p < 0.05, *** = p < 0.001. 
 
5.3.2 Effects of AdHIFs on muscle energy metabolism 
In addition to the angiogenic response, the effects of HIFs on skeletal muscle metabolism were 
also a major subject of interest. 31P-MRS was used to measure energy metabolism in the 
ischemic hindlimbs of rabbits. Aerobic capacity, as depicted by the ratio PCr/(PCr+Pi) at the end 
of the exercise period, declined in all the study groups (Figure 21). At d0, only intact muscles 
were able to properly recover from exercise and restore PCr, while the PCr/(PCr + Pi) ratios in 
the ischemic muscles remained at low and comparable levels during the course of recovery. Six 
days after GT, AdHIF-1α transduced muscles replenished PCr storage markedly better than 
AdLacZ transduced muscles. By d6, recovery of AdHIF-2α transduced muscles from exercise 
had returned back to baseline but did not significantly differ from the recovery of AdLacZ 
muscles. 
 
Figure 21. PCr/(PCr+Pi) ratios representing aerobic capacity and recovery rate one day after the 
ischemia procedure (d0) and six days after gene transfer (d6). AdHIF-1α improved recovery of 
ischemic muscles from exercise 6 days after GT. 
 
5.3.3 Upregulation of HIF target genes following AdHIF-1α and AdHIF-2α GTs 
At protein level, VEGF-A was detectable in immunohistochemically stained sections of AdHIF-
1α and AdHIF-2α transduced muscles, whereas AdLacZ muscles expressed no VEGF-A. 
Moreover, eNOS was markedly upregulated in AdHIF-2α transduced muscles and to a lesser 
extent also in AdHIF-1α muscles. At the mRNA level in vitro, AdHIF-1α upregulated PDK1 
more vigorously than AdHIF-2α. In contrast, VEGF-A mRNA expression in ECs was higher 
after transduction with AdHIF-2α than with AdHIF-1. 
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6 Discussion 
6.1 LYMPHANGIOGENIC GENE THERAPY FOR LYMPHEDEMA (I-II) 
Secondary lymphedema remains a common clinical challenge after oncologic surgery and 
radiation therapy in the industrialized countries. Breast cancer as well as melanoma of the 
extremities are good examples of high prevalence tumors with a tendency to develop lymphatic 
metastasis (Scoggings et al. 2005). Removal or irradiation of draining lymph nodes is a key 
prognostic factor when treating these malignancies (Chang et al. 2013). Alas, such treatments 
often lead to seconday lymphedema. A recent meta-analysis revealed that approximately one in 
five women with breast cancer will develop lymphedema (DiSipio et al. 2013). Autologous 
lymph node transfer, which is intended to rebuild the normal lymphatic vascular anatomy and 
function after cancer treatment, represents as a promising novel approach to treat this condition 
that has no curative treatment at present (Saaristo et al. 2012, Becker et al. 2006). A shortcoming 
of this approach is a prerequisite that lymphatic anastomoses form spontaneously and 
incorporate the transferred lymph node flap into the existing lymphatic vasculature at the 
lymphedema-subjected area. Lymph nodes left without lymphatic vasculature are known to 
regress, necessitating the formation of lymphatic connections between the transplant and the 
recipient site for successful result of the treatment (Mebius et al. 1991).  
In this thesis, a gene therapeutic approach was adopted to promote integration of the lymph 
node graft and restore damaged lymphatic function. A novel large animal model of 
lymphedema was developed to better mimick the features of the human lymphatic circulation, 
the most important features being the similar hydrostatic conditions and lymphatic vessel 
dimensions shared by humans and pigs. Previous studies of therapeutic lymphangiogenesis 
have been mostly performed using rodent lymphedema models, where the regenerating 
lymphatics only need to grow over an area measurable in millimeters to repair the damage in 
lymphatic network (Tammela et al. 2007, Yoon et al. 2003, Szuba et al. 2002, Saaristo et al. 2002a, 
Karkkainen et al. 2001). In the pig model used in this thesis, lymphatic neovessels need to span 
a length of 5 centimeters if they are to form anastomoses with the distal and proximal ends of 
the existing lymphatic vascular tree. Although some spontaneously growing lymphatic vessels 
of this magnitude were detected in control animals, the stimulation of lymphatic growth with 
adenoviral VEGF-C and VEGF-D proved to be effective in inducing robust growth of functional 
collecting lymphatic vessels to the site of surgical damage. These lymphatic neovessels were 
still observable after a two-month follow-up, even though the adenoviral over-expression of 
delivered growth factors lasts for only up to two weeks. Hence, long-term growth factor 
expression may not be required to achieve a maintained therapeutic effect. Importantly, the 
newly formed lymphatic vessels were also found to improve lymphatic flow in the damaged 
area. 
It seems likely that due to the successful integration of the lymphatic neovessels into the pre-
existing lymphatic network and consequential improvement in lymphatic flow, the lymph node 
size and histological architecture were best preserved in those animals transduced with 
AdVEGF-C and almost as well in animals receiving AdVEGF-D. Animals receiving control gene 
AdLacZ or saline displayed smaller lymph nodes than those in the therapeutic treatment 
groups, with fibro-fatty formations replacing parts of the normal follicular structure. Due to 
immune cell trafficking through the lymph node, the preservation of histological architecture is 
crucial to its function. The use of Lipiodol as a radio-opaque contrast agent in this thesis may 
have affected the size measurements and histology evaluations, as Lipiodol has been shown to 
influence lymph node size and to be retained in lymph nodes for 12 months on average (McIvor 
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1980). This might explain why the AdVEGF-C-treated lymph nodes were slightly, albeit not 
statistically significantly, larger than the intact left-side lymph nodes not perfused with 
Lipiodol. However, all the operated right-side lymph nodes were imaged using Lipiodol in a 
similar manner and treatment-related differences in size and histology were observed, 
warranting the conclusion that growth factor treatment may enhance the prognosis of the 
transferred lymph nodes. 
Despite offering a platform to study therapeutic interventions for lymphedema with an 
adequate scale, the pig model developed in this thesis possessed its own limitations. Unlike in 
chronic lymphedema, this model is based on acute lymphatic damage in otherwise young and 
healthy animals. In the clinical situation, lymphedema occurs mostly in older patients, where 
the initial accumulation of protein-rich fluid in the subcutaneous tissue is often complicated by 
fibrosis, increased lipid deposition, inflammation and attenuated immune responses (Rockson 
2001). No such changes were observed in the present model, as seroma fluid naturally 
dissipated within a few weeks after lymphatic excision even in the control groups. It would be 
preferable to develop a model of chronic lymphedema when investigating the potential of 
adenoviral growth factor therapy in severe states of the disease. However, autologous lymph 
node transfer can easily be performed in combination with breast reconstruction surgery 1 - 2 
years after oncological treatments of breast cancer without the need for a separate operation 
(Viitanen et al. 2013). At this stage, the secondary changes of lymphedema have not occurred 
yet and the patients are likely to benefit most from lymph node transfer. From this perspective, 
the pig model of acute lymphatic damage investigated in this thesis serves its purpose as a 
proof-of-concept model to test the efficacy of lymph node transfer in combination with 
lymphangiogenic gene therapy before conducting clinical trials. 
Intriguingly, despite possessing similar lymphangiogenic effects, AdVEGF-D appeared to 
provoke more blood vascular effects than AdVEGF-C. Blood capillaries were more dilated, their 
permeability increased, and seroma volumes were greater after application of AdVEGF-D in 
comparison to AdVEGF-C and control. Proteolytically processed short forms of VEGF-C and 
VEGF-D are known to bind with high affinity to VEGFR-2, and these forms can induce 
angiogenesis and vessel hyperpermeability (Anisimov et al. 2009, McColl et al. 2007, Achen et 
al. 1998, Joukov et al. 1997). The short isoform of VEGF-D, VEGF-DΔNΔC, has been linked to an 
increase in pericardial effusion when injected into the heart at high doses, as well as in notable 
vascular permeability and subsequent edema in transduced hindlimbs (Rutanen et al. 2004, 
Rissanen et al. 2003b). Thus, hyperpermeability of angiogenic vessels induced by VEGF-DΔNΔC 
could account for the observed increase in seroma fluid in the AdVEGF-D group, at least to 
some extent. Western Blot analysis of seroma fluids provided evidence of more extensive 
processing of the full-length VEGF-D protein into its short isoform in comparison to VEGF-C, 
indicating that there were substantial amounts of VEGF-DΔNΔC present in the seroma fluid. 
However, in the Western Blot analysis, human antibodies were used to detect VEGF-C and 
VEGF-D proteins, and even though these had originated from human transgenes, they had been 
processed into their short isoforms by endogenous porcine proteases. There is no certainty that 
the recognizion of these processed isoforms by human antibodies was complete. Another 
possible factor interfering with the accuracy of this assay could be cross-reactivity between 
human-origin short isoforms and endogenous porcine short isoforms. 
VEGF-C was selected for further study due to its slightly superior lymphangiogenic and 
lesser angiogenic effects than VEGF-D. Using the same pig model of lymphedema, AdVEGF-C 
was injected under the capsule of the lymph node similarly as in the first study, or into the fat 
surrounding the node, with the objective to determine the efficacy and potential adverse effects 
of both administration routes. Perinodally administered AdVEGF-C proved to be as effective in 
inducing growth of new lymphatic vessels as intranodally injected AdVEGF-C. The architecture 
as well as the size of lymph nodes were equally well preserved in both treatment groups. 
However, gene transfer into the perinodal fat appeared to be gentler to the grafted lymph node. 
Pigs receiving intranodal injections of AdVEGF-C displayed increased macrophage infiltration 
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inside the lymph node two months after gene transfer. Since a similar increase in the numbers 
of macrophages was also observed in animals receiving intranodal AdLacZ, it would appear 
that the macrophage accumulation was due to the adenoviral vector or mechanical damage 
caused by the injections. However, this result should be viewed with caution since the HAM56 
antibody used here to identify macrophages labels ECs as well, which may hamper the reliable 
quantification of the pure macrophage population (Gown, Tsukada & Ross 1986). The 
adenovirus vector per se has been associated with a prominent inflammatory reaction, but the 
innate inflammatory response mediated by macrophages against the adenovirus would be 
expected to have subsided two months after vector administration (Schnell et al. 2001, Zhang et 
al. 2001, Worgall et al. 1997, Simon et al. 1993). One possible explanation for the increased 
macrophage number at the site of vector distribution could be that the high local concentrations 
of the adenoviral vector inside the lymph node had elicited cytotoxicity, leading to loss of 
transduced cells, which would then be removed by macrophages. High doses of the adenoviral 
vector are known to cause cytotoxicity of the target cells and chronic inflammation, at least in 
neuronal tissue (Thomas et al. 2001). Moreover, macrophages have been shown to phagocytose 
adenovirus vector-transduced cells in mouse brain (Zirger et al. 2012). Phagocytosis marks a 
late stage in the process of transduced cell death. In general, local administrations of reasonable 
doses (109 - 1011 vp) of the adenoviral vector have been claimed to be well tolerated (Harvey et 
al. 2002). In the perinodally treated lymph nodes, sparse macrophages lined the subcapsular 
and trabecular sinuses and no such clustering was observed as in the intranodally treated 
lymph nodes. These findings favor the administration of AdVEGF-C into the perinodal fat of 
the lymph node graft.  
One important aspect when one considers future clinical trials is the ability of lymphatic 
growth factors to promote lymphatic metastasis of tumor cells, even spontaneous tumor 
formation (Karkkainen et al. 2009, Hirakawa et al. 2007, Ishii et al. 2004, Skobe et al. 2001). It is 
possible that the viral construct or the protein product could diffuse from the injection site to 
other organs and cause undesirable side effects. Although the safety samples collected from 
internal organs in the first study of this thesis showed no signs of pathological changes, the 
toxicity of AdVEGF-C will need to be more comprehensively evaluated in a separate study 
prior to clinical testing. Patient safety is a key issue when identifying recipients for this 
treatment in clinical trials. However, VEGF-C, which is constantly produced by normal human 
lymph nodes in small amounts, was only transiently (~ 1 week) over-expressed in the treatment 
strategy explored in this thesis. Nonetheless, the risks and benefits of combined lymph node 
transfer and AdVEGF-C over-expression will need to be carefully weighed especially in patients 
with a history of malignant disease. Lymph node transfer in itself may provide added benefit 
for these patients in their battle against cancer recurrence, since grafted lymph nodes have been 
shown to maintain the ability to trap tumor cells and mount a cytotoxic immune response 
against cancer cells (Tammela et al. 2007, Rabson et al. 1982). 
The ultimate selection of the growth factor to be taken into clinical testing requires a 
thorough examination of the advantages and disadvantages of each candidate. VEGF-C was 
proven to be the preferred growth factor over VEGF-D in this thesis. In addition to these two 
contenders, an engineered variant of VEGF-C (VEGF-C156S) exists, which is a selective agonist 
of VEGFR-3 and believed to induce only lymphangiogenesis without any angiogenic effects. 
Nonetheless, this growth factor exhibited inferior lymphangiogenic potential compared to 
VEGF-C in a recent study conducted in the same pig model of lymphedema as employed in this 
thesis (Visuri et al., unpublished results). A similar observation was also made in a mouse 
model of lymphedema and lymph node transfer (Tervala et al. 2015). Based on these findings 
and the results obtained in this thesis, VEGF-C can be considered to represent the primary 
candidate for lymphangiogenic gene therapy trials due to its superior lymphangiogenic efficacy 
and negligible vascular effects as compared to VEGF-D. A summary of the effects of these 
growth factors observed in this thesis is presented in figure 22. 
 
64 
 
 
 
Figure 22. A summary of the effects of VEGF-C and VEGF-D on blood and lymphatic vasculature 
observed in this thesis. 
 
6.2 PHYSIOLOGICAL ANGIOGENESIS INDUCED BY HIFS (III) 
The aim of the third study of this thesis was to examine the activation of several factors 
involved in angiogenesis via AdHIFs in order to achieve a more physiologigal angiogenic 
response than could be achieved by over-expressing a single proangiogenic factor. VEGF-A, for 
example, is known to induce robust angiogenesis, which is unfortunately accompanied by side 
effects such as notable tissue edema and the formation of immature, leaky vascular structures 
(Karvinen et al. 2011, Weis, Cheresh 2005). Hypoxia-inducible factors function as master 
regulators of angiogenesis and vascular remodeling by coordinately regulating the expression 
of several downstream target genes that play key roles in mediating vascular responses to 
ischemia (Semenza 2014). Thus, it has been hypothesized that gene transfer of these 
transcription factors may lead to more physiological angiogenesis by turning on several genes 
simultaneously. 
The effects of AdHIF-1α and AdHIF-2α gene transfers on angiogenesis were studied in 
normoxic mouse myocardium as well as in normoxic and ischemic rabbit skeletal muscles. The 
use of stabilized forms of HIF-1α and HIF-2α in viral constructs decreased their normal 
proteolytic degradation under normoxic conditions. Indeed, both AdHIFs induced capillary 
enlargement in all target tissues when they were assessed under the miscroscope; this effect was 
moderate compared to the effect of AdVEGF-A. The capillaries appeared to have a uniform 
shape after AdHIF-1α/-2α GTs in contrast to the disorganized and greatly enlarged capillaries 
induced by AdVEGF-A. Tissue edema, which commonly accompanies severe capillary 
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dilatation, was markedly evident in AdVEGF-A transduced muscles, whereas no harmful 
edema was observed after AdHIF-1α and AdHIF-2α gene transfers. Taken together, these 
findings support the working hypothesis that HIFs lead to more physiological angiogenesis 
than VEGF-A on its own. Additionally, AdHIFs appeared to enhance collateral vessel opening 
in comparison to AdLacZ as determined by DSA in ischemic rabbit hindlimbs. 
Perfusion measurements by ultrasound imaging techniques were performed with the 
objective to answer the question of whether the angiogenic effect induced by HIFs would be 
adequate to improve muscle circulation at rest and, furthermore, to improve perfusion recovery 
after exercise. Perfusion at rest 6 days after GT was approximately 4-fold higher in the AdHIF 
treatment groups than in controls, and even several-fold higher than that in the AdVEGF-A 
transduced muscles, which is in accordance with the histological capillary measurements. 
Contrast pulse imaging (CPS), which was used here to quantify perfusion, has been shown to be 
more accurate at the capillary level than the traditional native Doppler technique, which 
revealed no significant difference in perfusion between AdHIFs and negative control in this 
study (Rissanen et al. 2008). Interestingly, AdHIF-2α but not AdHIF-1α resulted in enhanced 
perfusion recovery from exercise in ischemic limbs from day 0 to day 6 after GT, as quantified 
by CPS. This study was the first to report improved blood flow by HIF-2α in large animal 
skeletal muscle. 
AdHIF-2α also appeared to exert cardioprotective effects in the mouse myocardium. The 
contractility of the left ventricle was maintained at the basal level 6 days after GT in AdHIF-2α 
transduced mice hearts, whereas a decrease in the ejection fraction was observed in AdHIF-1α 
and AdLacZ transduced hearts. The reduced cardiac function in these groups may have been 
attributable to the gene transfer procedure itself possibly inflicting mechanical damage to the 
tiny hearts of mice, as well as the inflammation and edema caused by the adenoviral vector 
(Merentie et al., unpublished results). These interfering factors, tissue damage and 
inflammation, may also hamper reliable quantification of cardiac function, which will warrant 
further confirmation of the observation that AdHIF-2α could protect the myocardium. The 
stable HIF expression achieved by genetic modification or siRNA transfection has been shown 
previously to protect mouse myocardium from an ischemic insult (Holscher et al. 2011, 
Hyvarinen et al. 2010, Natarajan et al. 2006). However, there are also reports indicating that 
chronic activation of HIFs could result in heart failure that mimicks ischemic cardiomyopathy 
(Holscher et al. 2012, Moslehi et al. 2010). Hence, the role of HIFs in cardioprotection versus 
cardiac injury remains to be fully characterized. 
An ideal gene therapy construct would not only increase vascularity and perfusion but also 
improve energy metabolism of the target tissue as an indicator of the functionality of the 
induced vessels. In this study, changes in muscle energy metabolism in the context of exercise 
following AdHIF gene transfers were evaluated using 31P-MRS, which can be used to assess the 
metabolic correlates of tissue perfusion in a noninvasive manner. AdHIF-1α, in particular, 
improved the recovery of ischemic limbs from the energy loss induced by electrical stimulation 
in comparison to AdLacZ. This is in line with previous findings from a study performed in a 
transgenic mouse model that revealed an unchanged cellular energy state after ischemia as a 
result of stable HIF-1 and HIF-2 expression (Hyvarinen et al. 2010). However, neither of the 
AdHIFs improved exercise tolerance of the ischemic limbs in this study, which has been 
previously shown for AdPlGF and AdVEGF-A by 31P-MRS using a similar rest-exercise-
recovery protocol (Korpisalo et al. 2008b, Gowdak et al. 2000). It is possible that different 
growth factors and stimulators of angiogenesis influence different phases in muscle energy 
metabolism. Altogether, it was observed that the angiogenic effect induced by AdHIF-1α 
resulted in metabolic improvements, indicative of normal function of the angiogenic vessels. 
31P-MRS is a relevant method for obtaining objective information about the energy state and 
function of muscles and its values have been shown to correlate with several clinical parameters 
such as the ankle-brachial index in patients with PAD (Greiner et al. 2006). In future studies of 
proangiogenic gene therapy, muscle metabolism could also be measured by 18FDG PET, which 
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utilizes radiolabeled glucose to reveal the metabolic status of tissue (Pappas, Olcott & Drace 
2001). 
In summary, the dilation of capillaries, increased muscle perfusion, and the elevated number 
of opened collaterals observed after gene transfer with AdHIFs resulted in enhanced recovery 
of ischemic muscles from exercise in the experimental ischemic animal model employed in this 
study. It should be noted, however, that this study was performed in young, healthy animals, 
and the ischemia was caused by ligating an artery causing an abrupt change in blood flow. The 
pathophysiology involved in the gradual occlusion of arteries in chronic human atherosclerotic 
disease differs considerably from the acute ligation of healthy arteries. Indeed, the therapeutic 
potential of AdHIF-1α has been called into question by a recent clinical trial that showed no 
benefit from AdHIF-1 GT in the treatment of intermittent claudication of PAD patients (Creager 
et al. 2011). There has been a trend among angiogenic gene therapy studies that the promising 
results obtained in experimental models cannot be replicated in clinical trials. Several reasons 
have been postulated to account for this discrepancy, such as inadequate dosing, insufficient 
duration of exposure to the angiogenic agent, compromised delivery and poor vector 
transduction efficiency (Dragneva, Korpisalo & Yla-Herttuala 2013). The species-, age-, and 
health-related differences between animal models and patients, as discussed above, may also 
account for the failure in the translation of techniques optimized in animals to the human 
clinical population. In future preclinical studies of proangiogenic gene therapy, it would be 
advisable to favour large animals rather than rodents, and, instead of using young and healthy 
animals, to employ disease models such as atherosclerotic or diabetic models that better mimick 
ischemic disease in humans. 
Taken together, the three studies included in this thesis revealed that adenoviral gene 
transfer as a tool to induce neovessel growth, whether it be angiogenic or lymphangiogenic, is 
sufficient to achieve effects that lead not only to histological changes in the target tissue, but 
also achieve functional improvements. AdVEGF-C and Ad-VEGF-D improved lymphatic flow 
through the induction of lymphangiogenesis, whereas angiogenesis triggered by AdHIF-1α in 
ischemic muscles led to improved energy recovery after exercise. Importantly, these effects 
were demonstrated using large mammals, which adds to their relevance with regard to their 
potential clinical translation.  Notable angiogenic and lymphangiogenic effects were observed 
both when the expression of only a single growth factor, such as VEGF-C or VEGF-D in the first 
two studies or VEGF-A in the third study, was altered, and when transcription factors HIF-1α/-
2α, which govern the expression of several growth factors, were administered. The concept of 
employing a “master-switch” agent rather than a single growth factor to yield a more 
physiological induction of neovessel growth is not a new concept in therapeutic angiogenesis. 
Already in the year 2000, a consensus statement by a panel of researchers in this field proposed 
that a combination of angiogenic cytokines or the use of transcription factors that upregulate 
several genes may be optimal for clinically beneficial therapeutic angiogenesis (Simons et al. 
2000). Experimental support for this strategy had been obtained previously from studies in 
transgenic mice: the over-expression of VEGF-A was found to induce formation of 
hyperpermeable blood vessels and subsequent edema in the skin of mice, whereas 
simultaneous over-expression of VEGF-A and ANG1 produced vessels that were not leaky 
(Thurston et al. 1999, Larcher et al. 1998). Although the direct over-expression of VEGF-C via 
adenoviral vectors studied in this thesis was found to be effective without side-effects, the 
modulation of VEGF-C activity as a way of stimulating therapeutic lymphangiogenesis only 
emerged recently, when CCBE1 was shown to be a strong activator of VEGF-C. In one 
experiment, mouse skeletal muscles displayed significantly enhanced lymphangiogenesis when 
transduced with AAV vectors expressing both CCBE1 and VEGF-C, as compared to 
transduction with AAV expressing VEGF-C alone. (Jeltsch et al. 2014.) Hence, the 
implementation of several factors may also confer added benefit in the field of therapeutic 
lymphangiogenesis. 
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7 Conclusions and future perspectives 
 
The following conclusions can be drawn from the individual studies (I-III) of this thesis: 
 
I Short-term adenoviral over-expression of both VEGF-C and VEGF-D led to 
pronounced lymphangiogenesis which was sufficient to improve lymphatic flow 
and to retain the architecture of the grafted lymph node. AdVEGF-D increased 
seroma formation as compared to AdVEGF-C and appeared not only to have 
lymphatic effects but also blood vascular effects were noted. 
 
II AdVEGF-C gene transfer performed into the fat surrounding the lymph node graft 
is the preferred method of administering lymphangiogenic gene therapy in 
prospective clinical trials of lymphedema. 
 
III Transient adenoviral over-expression of HIFs resulted in the enlargement of 
capillaries and an increase in muscle perfusion that was sufficient to improve the 
metabolic recovery of rabbit ischemic skeletal muscle from exercise. Influencing 
several angiogenic factors at a more upstream level by using HIFs leads to a more 
physiological angiogenic response than the use of a single, strong angiogenic 
growth factor such as VEGF-A. 
 
In summary, adenovirus-mediated, transient over-expression of growth factors is sufficient to 
induce lymphatic and blood vessel growth, which results in measurable functional effects, such 
as improvements in lymphatic flow and enhanced energy metabolism in ischemic muscles. 
Although the over-expression of a single growth factor may be sufficient to achieve these 
effects, the upregulation of several growth factors rather than simply one factor might represent 
an alternative therapeutic target since it may achieve a more physiological response and thus be 
less likely to cause side-effects. 
Specifically, the adenoviral VEGF-C gene therapy studied in this thesis may provide a 
treatment option for lymphedema patients when administered in conjunction with the lymph 
node transfer procedure. AdVEGF-C could easily be injected into the edges of a lymphatic 
tissue flap harvested from the patient’s abdominal wall and inserted to the recipient site in the 
lymphedematous area. A phase I/II clinical trial to evaluate the safety and efficacy of adenoviral 
VEGF-C in the treatment of secondary lymphedema is being designed and scheduled to begin 
in the near future.  
For the transcription factor HIF-1α/2α gene therapy, further pre-clinical studies are needed, 
and the adequate dosing and duration of therapy, end-points, and potential patient populations 
will have to be re-evaluated before drawing any final conclusions about the potential benefits of 
this therapy in the treatment of cardiovascular diseases.  
 .
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New Treatment Strategies for Lymphedema 
and Peripheral Ischemia
In this thesis, gene therapeutic 
approaches for the treatment 
of lymphedema and peripheral 
ischemia, which result from 
insufficiency of lymphatic and blood 
vessels, respectively, are described. 
Adenoviral VEGF-C and VEGF-D 
were shown to induce robust 
lymphangiogenesis and, subsequently, 
improve lymphatic flow. Furthermore, 
the angiogenic response triggered 
by adenovirally delivered hypoxia-
inducible factors was shown to 
enhance the recovery of ischemic 
muscles from energy depletion 
induced by exercise.
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